Multiplexed crispr genotyping for APOL1

WO2024220581A3PCT designated stage expired Publication Date: 2024-12-05THE GENERAL HOSPITAL CORP +3
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/025047
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-17
Filing Date
2024-04-17
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current CRISPR-based genotyping methods are limited in detecting multiple APOL1 variants in a single reaction and are not optimized for multiplexing, which hampers their application in larger clinical cohorts and point-of-care settings, particularly in identifying genetic susceptibility to kidney diseases prevalent among individuals of sub-Saharan African ancestry.

Method used

A nucleic acid detection system utilizing Cas nucleases such as LwaCas13a, PsmCas13b, and LbaCas12a, combined with specific crRNAs and a reporter system, enables the multiplexed detection of APOL1 genotypes, including G1 and G2 variants, in a single reaction, using a lateral flow strip for rapid and accurate genotyping.

Benefits of technology

This approach allows for the simultaneous detection of six APOL1 genotypes, improving the accuracy and speed of genotyping, making it suitable for point-of-care applications and enhancing the identification of genetic risk factors for kidney diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024025047_05122024_PF_FP_ABST
    Figure US2024025047_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The invention features compositions and methods for multiplexed, point-of-care compatible CRISPR assays for precise genotyping of human APOL1 variants.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] MULTIPLEXED CRISPR GENOTYPING FOR APOL1

[0002] CROSS-REFERENCE TO RELATED APPLICATION

[0003] This application claims the benefit of U.S. Patent Application Serial No. 63 / 459,750, filed on April 17, 2023. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.

[0004] BACKGROUND OF THE INVENTION

[0005] CRISPR diagnostics enable sensitive and specific detection of DNA and RNA biomarkers at the point-of-care. The single nucleotide specificity of Cas enzymes makes them promising tools for rapid genotyping in point-of-care settings. However, while these methods have predominantly focused on pathogen detection, their potential for single nucleotide variant sensing has not yet been fully harnessed. Current CRISPR-based genotyping assays mainly rely on two guide RNAs to distinguish targets differing by a single base pair, yet they face challenges in robustly detecting heterozygous alleles. Further, these methods have not yet been optimized for multiplexing to enable the detection of multiple variants in a single reaction. Notably, the potential of CRISPR-based genotyping remains unexplored in larger clinical cohorts, impeding its validation and comparison with current clinical practices.

[0006] The disproportionate burden of non-diabetic kidney diseases among individuals of sub-Saharan African ancestry is evident, with a four-fold higher risk of developing end-stage kidney disease than those of Asian and Caucasian ethnicity. Initially, socioeconomic factors were proposed as the primary drivers of this disparity. However, the identification of high-risk variants (G1 and G2) of Apolipoprotein L1 (APOL1 ) has challenged this notion, revealing a genetic susceptibility as the key determinant. Carrying two risk variants (G1 G1 , G1 G2, or G2G2 - high-risk genotype) substantially increases the risk of kidney diseases, including hypertension-associated end-stage kidney disease (H-ESKD), focal segmental glomerulosclerosis (FSGS), and HIV-associated nephropathy (HIVAN). Furthermore, individuals receiving a high-risk genotype donor kidney exhibit worse kidney transplant outcomes and an increased likelihood of transplant failure.

[0007] Of significant relevance is the high APOL1 risk allele frequency, estimated as around 35% in the African American population in the United States, with approximately 13% of African Americans carrying two risk alleles. Presently, APOL1 genotyping is a costly process involving PCR followed by Sanger sequencing, with commercially available tests taking more than two weeks to deliver results. Furthermore, determination of APOL1 genotype in donor kidneys would allow better risk stratification posttransplantation, complementing donor race from the current risk calculator. Currently, race is employed as a rudimentary indicator of APOL1 -mediated kidney disease risk in clinical practice. However, this proves inadequate as the majority of individuals with recent African ancestry do not carry a high-risk genotype.

[0008] SUMMARY OF THE INVENTION

[0009] In one aspect, the invention features a nucleic acid detection system including: (a) a Cas nuclease; (b) a crRNA that specifically binds to an APOL1 target nucleic acid; and (c) a reporter cleavable by the Cas nuclease. In some embodiments, the Cas nuclease is a Cas13 nuclease. In some embodiments, the Cas13 nuclease is LwaCas13a. In some embodiments, the Cas13 nuclease is PsmCas13b.

[0010] In some embodiments, the Cas nuclease is a Cas12 nuclease. In some embodiments, the Cas12 nuclease is LbaCas12a.

[0011] In some embodiments, the crRNA specifically binds to a G1 variant APOL1 nucleic acid. In some embodiments, the crRNA includes the nucleic acid sequence of any one of crRNAI -crRNA9.

[0012] In some embodiments, the crRNA specifically binds to a G2 variant APOL1 nucleic acid. In some embodiments, the crRNA includes the nucleic acid sequence of crRNA36 or crRNA37.

[0013] In some embodiments, the crRNA specifically binds to a GO wild-type APOL1 nucleic acid. In some embodiments, the crRNA includes the nucleic acid sequence of any one of crRNAI 0-crRNA35. In some embodiments, the crRNA includes the nucleic acid sequence of any one of crRNA38-crRNA45. In some embodiments, the crRNA includes the nucleic acid sequence of any one of crRNA46-crRNA66.

[0014] In some embodiments, the ratio of Cas nuclease: crRNA is about 2:1 .

[0015] In some embodiments, the reporter includes a fluorophore, a nucleic acid linker, and a quencher. In some embodiments, the reporter includes 5TEX615 / TArArUGC / 3IAbRQSp, 56- FAM / rUrUrUrUrU / 3IABkFQ, 56-FAM / rArArArArA / 3IABkFQ, 5TEX615 / rArArArArA / 3IAbRQSp, 5 Hexachlorofluorescein / TTATT / 3IABkFQ, or carboxyfluorescein / nucleic acid linker / quencher.

[0016] In some embodiments, the reporter includes a fluorophore, a nucleic acid linker, and a binding moiety. In some embodiments, the binding moiety is biotin or digoxigenin. In some embodiments, the reporter includes 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) or 56-FAM / TTATTATT / 3DigN.

[0017] In some embodiments, the nucleic acid detection system further includes an APOL1 target DNA.

[0018] In some embodiments, the nucleic acid detection system further includes an APOL1 target RNA.

[0019] In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0020] In some embodiments, the nucleic acid detection system includes (a) LwaCas13a; (b) crRNA5; and (c) carboxyfluorescein / nucleic acid linker / quencher.

[0021] In some embodiments, the nucleic acid detection system includes (a) PsmCas13b; (b) crRNA22; and (c) 5TEX615 / rArArArArA / 3IAbRQSp.

[0022] In some embodiments, the nucleic acid detection system includes: (a) LbaCas12a; (b) crRNA36; and (c) Hexachlorofluorescein / TTATT / 3IABkFQ.

[0023] In some embodiments, the nucleic acid detection system includes (a) a first Cas nuclease, a second Cas nuclease, and a third Cas nuclease; (b) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid, a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid, and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid; and (c) a reporter cleavable by the first Cas nuclease, a reporter cleavable by the second Cas nuclease, and a reporter cleavable by the third Cas nuclease. In some embodiments, each Cas nuclease is a different Cas nuclease. In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0024] In some embodiments, the nucleic acid detection system includes (a) LwaCas13a, PsmCas13b, and LbaCas12a; (b) crRNA5, crRNA22, and crRNA36; and (c) carboxyfluorescein / nucleic acid linker / quencher, 5TEX615 / rArArArArA / 3IAbRQSp, and Hexachlorofluorescein / TTATT / 3IABkFQ. In some embodiments, the nucleic acid detection system further includes a cleaved carboxyfluorescein / nucleic acid linker / quencher reporter, a cleaved 5TEX615 / rArArArArA / 3IAbRQSp reporter, or a cleaved Hexachlorofluorescein / TTATT / 3IABkFQ reporter.

[0025] In some embodiments, the nucleic acid detection system includes (a) a first Cas nuclease and a second Cas nuclease; (b) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid and a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid; and (c) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease. In some embodiments, each Cas nuclease is a different Cas nuclease. In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0026] In some embodiments, the nucleic acid detection system includes (a) LwaCas13a and LbaCas12a; (b) crRNA5 and crRNA41 ; and (c) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN. In some embodiments, the nucleic acid detection system further includes a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

[0027] In some embodiments, the nucleic acid detection system includes (a) a first Cas nuclease and a second Cas nuclease; (b) a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid; and (c) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease. In some embodiments, each Cas nuclease is a different Cas nuclease. In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0028] In some embodiments, the nucleic acid detection system includes (a) LwaCas13a and LbaCas12a; (b) crRNA62 and crRNA36; and (c) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN. In some embodiments, the nucleic acid detection system further includes a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

[0029] In another aspect, the invention features a lateral flow strip including: (a) the nucleic acid detection system described herein; (b) an application area; (c) one or more capture areas including an immobilized reagent; and (d) a control area.

[0030] In some embodiments, the application area includes nanoparticles including a plasmonresonance causing metal, wherein the surface of the nanoparticle includes an antibody that binds the reporter. In some embodiments, the plasmon-resonance causing metal includes gold. In some embodiments, the surface of the nanoparticle includes an anti-Fam antibody.

[0031] In some embodiments, the control area includes a secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle. In some embodiments, the control area includes a secondary anti-species specific antibody that binds the anti-Fam antibody.

[0032] In some embodiments, the lateral flow strip includes a first capture area that includes streptavidin and a second capture area that includes anti-digoxigenin.

[0033] In some embodiments, the lateral flow strip includes (a) a nucleic acid detection system including: (i) a first Cas nuclease and a second Cas nuclease; (ii) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid and a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid; and (iii) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease; (b) an application area including nanoparticles including a plasmon-resonance causing metal, wherein the surface of the nanoparticle includes an antibody that binds the reporter; (c) a capture area including a first immobilized reagent; (d) a capture area including a second immobilized reagent; and (e) a control area including a secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle. In some embodiments, each Cas nuclease is a different Cas nuclease. In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0034] In some embodiments, the lateral flow strip includes (a) a nucleic acid detection system including: (i) LwaCas13a and LbaCas12a; (ii) crRNA5 and crRNA41 ; and (iii) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN; (b) an application area including anti-Fam gold nanoparticles (AuNPs); (c) a capture area including streptavidin; (d) a capture area including anti- digoxigenin; and (e) a control area including a secondary anti-species specific antibody that binds AuNPs.

[0035] In some embodiments, the nucleic acid detection system further includes a cleaved 56- FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

[0036] In some embodiments, the lateral flow strip includes (a) a nucleic acid detection system including: (i) a first Cas nuclease and a second Cas nuclease; (ii) a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid; and (iii) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease; (b) an application area including nanoparticles including a plasmon-resonance causing metal, wherein the surface of the nanoparticle includes an antibody that binds the reporter; (c) a capture area including a first immobilized reagent; (d) a capture area including a second immobilized reagent; and (e) a control area including a secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle. In some embodiments, each Cas nuclease is a different Cas nuclease. In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0037] In some embodiments, the lateral flow strip includes (a) a nucleic acid detection system including: (i) LwaCas13a and LbaCas12a; (ii) crRNA62 and crRNA36; and (iii) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN; (b) an application area including anti-Fam gold nanoparticles (AuNPs); (c) a capture area including streptavidin; (d) a capture area including anti- digoxigenin; and (e) a control area including a secondary anti-species specific antibody that binds AuNPs. In some embodiments, the nucleic acid detection system further includes a cleaved 56- FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

[0038] In another aspect, the invention features a kit including one or more of the nucleic acid detection system described herein.

[0039] In another aspect, the invention features a kit including one or more of the lateral flow strips described herein.

[0040] In some embodiments, the kit further includes a genomic DNA isolation component.

[0041] In some embodiments, the kit further includes an amplification component. In some embodiments, the amplification component includes a DNA polymerase, a forward primer including the sequence of F9, and a reverse primer including the sequence of R7.

[0042] In another aspect, the invention features a method for determining a subject’s APOL1 genotype, including contacting a sample from the subject with a nucleic acid detection system described herein, a lateral flow strip described herein, or a kit described herein.

[0043] In some embodiments, the sample is a blood sample or a saliva sample.

[0044] In some embodiments, the genomic DNA of the sample is purified.

[0045] In some embodiments, the genomic DNA of the sample is amplified. In another aspect, the invention features a method for determining a subject’s APOL1 genotype, including: (a) providing an amplified blood sample from a subject; (b) incubating the amplified blood sample with a nucleic acid detection system described herein; and (c) detecting the reporter in said sample, thereby determining the subject’s APOL1 genotype.

[0046] In some embodiments, the detecting includes measuring the fluorescence of the reporter.

[0047] In another aspect, the invention features a method for determining a subject’s APOL1 genotype, including: (a) providing an amplified blood sample from a subject; (b) incubating the amplified blood sample with a nucleic acid detection system described herein; (c) applying the reaction of step (b) to a lateral flow strip; (d) detecting the reporter in the lateral flow strip, thereby determining the subject’s APOL1 genotype. In some embodiments, the detecting includes determining the presence or absence of a band in the capture area of the lateral flow strip.

[0048] Advantageously, the compositions and methods provided herein allow for the genotyping of more than one SNP using a CRISPR-based-assay. Previously designed CRISPR-based assays have genotyped for one variant. The present invention enables the genotyping of more than one variant in a single reaction. Specifically, the variants G1 and G2 that occur on the APOL1 gene are detected with this assay.

[0049] Moreover, the compositions and methods provided herein allow for the discrimination between more than 3 genotypes using a CRISPR-based assay. Using CRISPR-based detection methods, previous assays showed the ability to discriminate between samples that contain three different genotypes. The samples were wildtype, heterozygous, or homozygous for a variant. The present invention discriminates between more than 3 different genotypes using CRISPR-based methods. Specifically, the invention allows for the discrimination between six APOL1 genotypes (GOGO, G0G1 , G0G2, G1 G2, G1 G1 , G2G2).

[0050] Another advantage provided herein is the discrimination between homozygous, heterozygous, and wildtype using one Cas-crRNA complex. When detecting for a genetic variant, previous work has used one wildtype sensing Cas-crRNA complex and one mutant sensing Cas-crRNA complex in order to determine if a sample was wildtype, heterozygous, or homozygous. The present invention determines if a sample is wildtype, heterozygous, or homozygous for the APOL1 G1 variant using one Cas-crRNA complex.

[0051] A further advantage provided herein is the genotyping of a variant with one lateral-flow-based readout, such that a sample is determined to be wildtype, heterozygous, or homozygous. Previous literature has shown the ability to use one lateral flow stick for wildtype detection and a second lateral flow stick for mutant detection in order to genotype a sample for a variant. For each of the APOL1 variants G1 and G2, the present invention involves a multiplexed CRISPR-detection step. For genotyping for each of these variants, there is a wildtype and mutant sensing crRNA complex whose resulting collateral cleavage activities are read out on a lateral flow stick that contains two test bands. (With the conventional lateral flow-based readout, 2 sticks are needed per variant, adding up to 4 in total. In the present invention, only 2 sticks are needed in total).

[0052] Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims. Definitions

[0053] As used herein, the term “about” refers to a value that is within 10% above or below the value being described.

[0054] As used herein, the term “application area” refers to an area on a lateral flow strip where a nucleic acid detection system described herein is contacted.

[0055] As used herein, the term “capture area” refers to an area on a lateral flow strip including an immobilized reagent. Exemplary immobilized reagents include streptavidin and anti-dioxigenin.

[0056] As used herein, the term “Cas nuclease” refers any nucleic acid (DNA or RNA) targeting Cas nuclease. Cas nucleases allow for the targeting and cleavage of specific sequences by complexing with an RNA (e.g., a crRNA) that specifically hybridizes with a particular target sequence (cis-cleavage). In some embodiments, sequence-specific binding and cis-cleavage activity then initiates trans-cleavage activity (i.e. , multi-turnover activity) of the Cas nuclease, where trans-cleavage is indiscriminate and leads to non-sequence-specific cutting of nucleic acid molecules by the Cas nuclease.

[0057] As used herein, the term “contacting” refers to placement in direct physical association, including both in solid and liquid form.

[0058] As used herein, the term “crRNA” refers to a polynucleotide including a polynucleotide sequence having sufficient complementarity with a target nucleic acid sequence to hybridize with the target nucleic acid sequence and to direct sequence-specific binding of a Cas nuclease to the target nucleic acid sequence. In some example embodiments, the degree of complementarity, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.

[0059] As used herein, the term “control area” refers to an area on a lateral flow strip that is functionalized so that it will indicate that a sample has been applied to the lateral flow strip.

[0060] As used herein, “disorder” is used in this disclosure to mean, and is used interchangeably with, the terms condition, disease, or illness, unless otherwise indicated.

[0061] As used herein, the term “G1 APOL1 variant” refers to an APOL1 nucleic acid with a G342 mutation (dbSNP (Single Nucleotide Polymorphism Database) number rs73885319).

[0062] As used herein, the term “G2 APOL1 variant” refers to an APOL1 nucleic acid with a six-basepair (TTATAA) deletion that results in the loss of the amino acid residues 388N and 389Y (dbSNP (Single Nucleotide Polymorphism Database) number rs71785313).

[0063] As used herein, the term “GO APOL1 ” refers to a wild-type APOL1 nucleic acid that does not contain the G1 or G2 mutations.

[0064] As used herein, the term "nucleic acid" refers to any compound and / or substance that includes a polymer of nucleotides. Nucleic acid molecules of may be, for example, double-, or single-stranded deoxyribonucleic acid ("DNA"), as well as double- and single-stranded ribonucleic acid ("RNA”). The skilled artisan will appreciate that the T bases are present in DNA, whereas the T bases would be replaced by U bases in corresponding RNAs.

[0065] “Percent (%) sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acids in a candidate sequence that are identical to the amino acids in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the capabilities of one of skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For example, percent sequence identity values may be generated using the sequence comparison computer program BLAST. As an illustration, the percent sequence identity of a given amino acid sequence, A, to, with, or against a given amino acid sequence, B, (which can alternatively be phrased as a given amino acid sequence, A that has a certain percent sequence identity to, with, or against a given amino acid sequence, B) is calculated as follows:

[0066] 100 multiplied by (the fraction X / Y) where X is the number of amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in that program’s alignment of A and B, and where Y is the total number of amino acids in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the percent sequence identity of A to B will not equal the percent sequence identity of B to A.

[0067] As used herein, the term “plasmon-resonance causing metal” refers to any metal that produces surface plasmon resonance. Gold nanoparticles are useful for producing surface plasmon resonance, which results in dark colored bands on a lateral flow stick. Other metals useful for producing surface plasmon resonance include silver nanoparticles. Copper, titanium, or chromium are still other examples of metals producing surface plasmon-resonance.

[0068] As used herein, the term “reporter” refers to a molecule including (i) a fluorophore, (ii) a nucleic acid linker, and (iii) a quencher or a binding moiety. A “cleaved reporter” refers to a reporter that has been cleaved at its nucleic acid linker. Cleavage of the reporter releases the fluorophore from the quencher or the binding moiety.

[0069] As used herein, the term “target nucleic acid” refers to a sequence, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. For example, an “APOL1 target nucleic acid” refers to a nucleic acid including any portion or all of an APOL1 gene. The APOL1 target nucleic acid may be DNA or RNA to which a crRNA is designed to have complementarity. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization. A target sequence may comprise RNA polynucleotides. The term “target RNA“ refers to a RNA polynucleotide being or including the target sequence. In other words, the target RNA may be a RNA polynucleotide or a part of a RNA polynucleotide to which a part of the crRNA is designed to have complementarity. The target sequence may comprise DNA polynucleotides. The term “target DNA“ refers to a DNA polynucleotide being or including the target sequence. In other words, the target DNA may be a DNA polynucleotide or a part of a DNA polynucleotide to which a part of the crRNA is designed to have complementarity.

[0070] As used herein, the term “specifically binds” indicates that the binding is selective and can be discriminated from unwanted or non-specific interactions. Molecules and binding partner pairs that “specifically bind” generally have a Kd of at least 1 x10-6M or lower (e.g., in the range of 1 x10-6M to 1 x10_12M, such as 1 x107M, 1 x10sM, 1 x109M, 1 x10 M, 1 x1011M, and 1 x1012M).

[0071] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. For any term present in the art which is identical to any term expressly defined in this disclosure, the term's definition presented in this disclosure will control in all respects. Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods and materials are described herein.

[0072] BRIEF DESCRIPTION OF THE DRAWINGS

[0073] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application with color drawings will be provided by the Office upon request and payment of the necessary fee.

[0074] Figure 1 shows a crRNA optimization for the rapid detection of APOL1 risk variants, (a) Alignment of target sequences and LwaCas13a G1 mutant (mut) sensing crRNAs. The G1 wild-type (wt) sequence is highlighted in blue and the G1 mut sequence is highlighted dark orange. Bases in the crRNA that are only complementary to the G1 mut target are highlighted in light orange. Synthetic mismatches complementary to neither G1 mut or G1 wt are highlighted gray, (b) Screen for G1 mut sensing LwaCas13a crRNAs using synthetic RNA mimicking G1 wt targets (blue) and G1 mut targets (orange), (c) Alignment of target sequence and PsmCas13b G2 wt sensing crRNAs. Dark orange highlights the position of the 6 bp G2 wt sequence. Light orange indicates complementarity between the crRNA and its target, (d) Screen for G2 wt sensing PsmCas13b crRNAs using synthetic RNA mimicking G2 mut targets (blue) and G2 wt targets (orange). (b,d) Synthetic target RNAs were detected at an overall concentration of 15 nM and each data point represents an individual reaction. For each reaction, relative fluorescence units (RFUs) are shown at 3 hrs divided by the mean RFU value of the non-template control (NTC). Error bars: s.d. Statistical significance assessed with unpaired t test and shown as 0.0001 , ***p< 0.0002, **P< 0.0021 , *P< 0.0332; ns non-significant. For P values see: Table 7.

[0075] Figure 2 shows an optimization of RPA design for isothermal amplification, (a-c) Schematics above each graph show different forward (F) and reverse (R) primers tested in relation to the target to be amplified. The position of G1 and G2 variants are shown in orange. Relative fluorescence units (RFUs) shown at 3 hrs and each data point represents an individual reaction. Determining optimum RPA primer pair for amplification of DNA targets at an overall concentration of 100 fM (purple) and 2.5 fM (gray) for the G1 region (a), G2 region (b), G1 and G2 regions (c). (d) Primer optimization matrix assessing the indicated concentrations of forward and reverse primers. Primer pair used is F9R7 from c. Each data point represents an individual reaction, (a-c) Statistical significance assessed with one-way ANOVA and Tukey's multiple comparison's test for 100 fM and 2.5 fM targets as compared to optimum primer pair; P > 0.05 = not significant (ns), P < 0.05 (a), P < 0.01 (b), P < 0.001 (c), P < 0.0001 (d).

[0076] Figure 3 shows a comparison of APOL1 genotyping on synthetic and genomic DNA. (a-d) Multiplexed detection of DNA by LwaCas13a (a,c) and PsmCas13b (b,d). Synthetic DNA standards were detected at an overall concentration of 100 fM (a,b) and gDNA was detected at an overall concentration of 10 ng / pl (c,d). RPA was performed in duplicates for each sample and each RPA product was measured twice with the multiplexed CRISPR assay. Raw RFUs are shown and data are mean ± s.d. (e) Alignment of target sequences and G2 mutant sensing crRNAs (LbaCas12a). The spacer region of the crRNAs is shown in orange, and the protospacer adjacent motives (PAM) are highlighted yellow. The blue highlights the bases that are deleted in the case of G2. (f) crRNA testing for LbaCas12a. CRISPR assay sensing on-target (orange) and off-target (blue) synthetic DNA. Target DNA was detected at an overall concentration of 300 pM and each data point represents an individual reaction. For each reaction, relative RFUs are shown at 3 hrs divided by the mean NTC RFU value. Error bars: s.d. Statistical significance assessed with unpaired t test and shown as 0.0001 , ***p< 0.0002, **P< 0.0021 , *P< 0.0332; ns non-significant. For P values see: Table 7.

[0077] Figure 4 shows a multiplexed CRISPR-based detection of six APOL1 genotypes, (a) Orthogonality of Cas enzyme cleavage preference. CRISPR assay sensing on-target synthetic RNA at an overall concentration of 15 nM (LwaCas13a; PsmCas13b) or DNA at an overall concentration of 300 pM (LbaCas12a). Relative fluorescence units (RFUs) are shown at 3 hrs and heatmaps visualize the mean of 3 replicates, (b) Schematic illustrating the workflow of the multiplexed CRISPR-based assay. Genomic DNA is amplified by RPA. Amplified DNA is then detected in the CRISPR assay directly by LbaCas12a or transcribed to RNA before being detected by LwaCas13a and PsmCas13b. (c) Multiplexed detection of DNA standards that mimic the six APOL1 genotypes. RPA was performed in triplicates and measured once with the CRISPR assay. Raw RFUs are shown and data are mean + / - s.d. of three replicates, (d) Multiplexed detection of genomic DNA isolated from clinical samples. Synthetic DNA standard for normalization between experiments (square shaded half black). RPA was performed in duplicates and measured twice with the CRISPR assay. Background subtracted RFUs are shown, (e) Genotyping scores for data in d. (c-e) Data for LwaCas13a (upper panel; Fam channel), LbaCas12a (middle panel, Hex Channel), PsmCas13b (lower panel; Texas Red channel).

[0078] Figure 5 shows a CRISPR-based APOL1 genotyping in a multi-center patient cohort, (a) Schematic shows the workflow used to genotype patient samples for the APOL1 variants. Genomic DNA is amplified by RPA and then detected by the multiplexed CRISPR-based assay. Depending on the red, green, and orange signal intensities, the activity of LwaCas13a, PsmCas13b, and LbaCas12a, respectively, is measured. There are six unique combinations of signal intensities possible that each determine what APOL1 genotype is present as summarized in the table on the right, (b) Box plots show resulting data of samples from the USA and Germany cohorts that have been genotyped with the multiplexed CRISPR-based assay. The data for LwaCas13a, LbaCas12a, and PsmCas13b are shown on the left, middle, and right, respectively. Data is the mean of six replicates with each point representing a different patient. Dashed lines indicate genotype score thresholds, (c) Schematic of the machine learning model, (d) Confusion matrix summarizing accuracy of CRISPR-based (predicted) genotyping for six APOL1 genotypes determined by the machine learning model, as compared to Sanger Sequencing determined (true) genotypes. Boxes shaded blue indicate a true positive result.

[0079] Figure 6 shows a CRISPR-based APOL1 genotyping by genotype scores. Confusion matrix summarizing accuracy of CRISPR-based (predicted) genotyping for six APOL1 genotypes as compared to Sanger Sequencing determined (true) genotypes for US and German cohort as shown in Fig. 5b. Numbers indicate patients and boxes shaded blue indicate a true positive result.

[0080] Figure 7 shows an APOL1 genotyping of independent Brazilian cohort. Box plots show genotype scores of patient samples from the Brazilian cohort. The data for LwaCas13a, LbaCas12a, and PsmCas13b are shown on the left, middle, and right, respectively. Each data point represents an individual reaction. Dashed lines indicate genotype score thresholds. Figure 8 shows a multi-analyte lateral-flow readout of multiplexed CRISPR-genotyping. (a) Schematic illustrating the lateral-flow-based assay. Multiplexed CRISPR detection by LbaCas12a and LwaCas13a for APOL1 alleles G1 (top) and G2 (bottom). Upon target recognition, the collateral cleavage of reporter molecules results in the absence of gold nanoparticles at the corresponding test band, (b) Lateral-flow-based visualization of APOL1 genotyping. RPAs performed in triplicates and each RPA product measured once with multiplexed G1 and G2 assays. Representative images for each genotype shown above; data indicates ratios of test band to control band intensity and is displayed as the mean ± s.d. of three reactions. Dashed line indicates a relative band intensity of 0.5.

[0081] Figure 9 shows a crRNA screening for lateral-flow-based APOL1 genotyping, (a) Alignment of target sequences and LbaCas12a G1 wildtype sensing crRNAs. The spacers of the crRNAs are shown in orange, and the corresponding PAMs are shown in yellow. Bases only present in the case of G1 wt are highlighted in dark orange, (b) Screen for G1 wt sensing LbaCas12a crRNAs detecting on (orange) and off-target (blue) synthetic DNA. DNA was detected at an overall concentration of 100 fM. RPA was performed in duplicates for each sample and each RPA product was measured twice with the CRISPR assay. Each data point represents an individual reaction. For each reaction, relative RFUs are shown at 2 hrs divided by the mean NTC RFU value, (c) Alignment of target sequence and LwaCas13a G2 wt sensing crRNAs. Dark orange highlights the position of the 6 bp G2 wt sequence and crRNA spacers are shown in light orange, (d) Screen for G2 wt sensing LwaCas13a crRNAs detecting on (orange) and off- target (blue) synthetic RNA. RNA detected at an overall concentration of 15 nM, each data point represents an individual reaction. RFUs are shown at 3 hrs divided by the mean RFU value of the nontemplate control. b,d. Error bars: s.d. Statistical significance assessed with unpaired t test and shown as ****P< 0.0001 , ***p< 0.0002, **P< 0.0021 , *P < 0.0332; ns non-significant. For P values see: Table 7.

[0082] DETAILED DESCRIPTION OF THE INVENTION

[0083] Detecting genetic pathogenic variants enables risk factor identification, early disease screening and initiation of preventative therapeutics. However, current methods, relying on complex hybridization or sequencing, are unsuitable for point-of-care settings. In contrast, CRISPR-based diagnostics offer high sensitivity and specificity for point-of-care applications. Although these methods have predominantly been used for pathogen sensing, their utilization for genotyping is limited. The disclosure provides methods and compositions for multiplexed, point-of-care compatible CRISPR assays for precise genotyping of human APOL1 variants. For example, a multiplexed CRISPR-based genotyping assay using LwaCas13a, PsmCas13b, and LbaCas12a is provided, enabling detection of six genotypes in a single reaction. The CRISPR-based, single reaction assay allows for accurate and fast determination of a patient's APOL1 genotype, encompassing all six possible genotypes (G0 / G0, G0 / G1 , G1 / G1 , G0 / G2, G1 / G2, G2 / G2). The assay leverages orthogonal cleavage properties of LwaCas13a, LbaCas12a and PsmCas13b to achieve multiplexed genotyping. The assay may be applied to identify genetic variants in the APOL1 gene prevalent among African Americans, which are associated with an 8 to 30-fold increase in the risk of developing kidney disease. Machine learning facilitated robust analysis across a multi-center clinical cohort of more than 100 patients, accurately identifying their genotypes. Also provided herein is a multianalyte lateral-flow assay, demonstrating the ability for simplified genotype determination without specialized equipment or expertise. The CRISPR-based genotyping assay of the invention enables cost- effective point-of-care genetic variant detection due to its simplicity, versatility, and fast readout. The multi-analyte lateral-flow-based readout achieves diagnostic accuracy comparable to sequencing.

[0084] I. APOL1

[0085] Human APOL1 variants represent a strong genetic risk factor for developing kidney disease and are prevalent in individuals of recent sub-Saharan African ancestry. The disclosure provides methods and compositions for determination of a patient's APOL1 genotype, encompassing all six possible genotypes (GO / GO, G0 / G1 , G1 / G1 , G0 / G2, G1 / G2, G2 / G2).

[0086] G1 codes for two amino acid substitutions, G342 and M384 (dbSNP (Single Nucleotide Polymorphism Database) numbers rs73885319 and rs60910145). These SNPs are in almost perfect linkage disequilibrium, but approximately 1% of haplotypes with the G342 allele do not contain the M384 allele. However, the risk of disease in cases where the G342 allele is present but not M384 is believed to be the same as when both alleles are present. Therefore, testing for G342 only is considered acceptable when assessing disease risk associated with the G1 variants. Thus, the methods and compositions provided herein sense the A:G SNP rs73885319 when detecting the G1 variant.

[0087] G2 (rs71785313), is a six-base-pair (TTATAA) deletion that results in the loss of the amino acid residues 388N and 389Y (dbSNP (Single Nucleotide Polymorphism Database) number rs71785313).

[0088] II. Nucleic acid detection systems

[0089] The disclosure provides APOL1 nucleic acid detection systems including (a) a Cas nuclease, (b) a crRNA that specifically binds to an APOL1 target nucleic acid, and (c) a reporter cleavable by the Cas nuclease. In some embodiments, the detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0090] In some embodiments, the ratio of Cas nuclease: crRNA is about 2:1 . In some embodiments, the ratio of Cas nuclease: crRNA is about 1 :1 . In some embodiments, the ratio of Cas nuclease: crRNA is about 3:1 .

[0091] In some embodiments, the nucleic acid detection system includes (a) LwaCas13a; (b) crRNA5; and (c) carboxyfluorescein / nucleic acid linker / quencher (e.g., a RNA linker). In some embodiments, the nucleic acid detection system includes (a) PsmCas13b; (b) crRNA22; and (c) 5TEX615 / rArArArArA / 3IAbRQSp. In some embodiments, the nucleic acid detection system includes (a) LbaCas12a; (b) crRNA36; and (c) Hexachlorofluorescein / TTATT / 3IABkFQ. In some embodiments, the detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0092] In some embodiments, the nucleic acid detection system includes (a) a first Cas nuclease, a second Cas nuclease, and a third Cas nuclease; (b) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid (e.g., any one of crRNAI -crRNA9), a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid (e.g., any one of crRNAI 0-crRNA35 or crRNA38-66), and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid (e.g., crRNA36 or crRNA37); and (c) a reporter cleavable by the first Cas nuclease, a reporter cleavable by the second Cas nuclease, and a reporter cleavable by the third Cas nuclease. In some embodiments, each Cas nuclease is a different Cas nuclease. In some embodiments, the detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0093] In some embodiments, the nucleic acid detection system includes (a) LwaCas13a, PsmCas13b, and LbaCas12a; (b) crRNA5, crRNA22, and crRNA36; and (c) carboxyfluorescein / nucleic acid linker / quencher, 5TEX615 / rArArArArA / 3IAbRQSp, and Hexachlorofluorescein / TTATT / 3IABkFQ. In some embodiments, the detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved carboxyfluorescein / nucleic acid linker / quencher reporter, a cleaved 5TEX615 / rArArArArA / 3IAbRQSp reporter, or a cleaved Hexachlorofluorescein / TTATT / 3IABkFQ reporter.

[0094] In some embodiments, the nucleic acid detection system includes (a) a first Cas nuclease and a second Cas nuclease; (b) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid (e.g., any one of crRNA1 -crRNA9) and a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid (e.g., any one of crRNA38-45); and (c) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease. In some embodiments, each Cas nuclease is a different Cas nuclease. In some embodiments, the detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0095] In some embodiments, the nucleic acid detection system includes (a) LwaCas13a and LbaCas12a; (b) crRNA5 and crRNA41 ; and (c) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN. In some embodiments, the detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

[0096] In some embodiments, the nucleic acid detection system includes (a) a first Cas nuclease and a second Cas nuclease; (b) a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid (e.g., any one of crRNAI 0-crRNA35 or crRNA46-66) and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid (e.g., crRNA36 or crRNA37); and (c) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease. In some embodiments, each Cas nuclease is a different Cas nuclease. In some embodiments, the detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved reporter.

[0097] In some embodiments, the nucleic acid detection system includes (a) LwaCas13a and LbaCas12a; (b) crRNA62 and crRNA36; and (c) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN. In some embodiments, the detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter. 1. Cas nucleases

[0098] Cas nucleases allow for the targeting and cleavage of specific sequences by complexing with an RNA (e.g., a crRNA) that specifically hybridizes with a particular target sequence (cis-cleavage). In some embodiments, sequence-specific binding and cis-cleavage activity then initiates trans-cleavage activity (i.e. , multi-turnover activity) of the Cas nuclease, where trans-cleavage is indiscriminate and leads to nonsequence-specific cutting of nucleic acid molecules by the Cas nuclease.

[0099] In some embodiments, the Cas nuclease is a Cas13 nuclease. Cas13 nucleases cleave RNA and exhibit collateral activity after recognition and cleavage of a target molecule, leading to non-specific degradation of any nearby RNA regardless of complementarity to the crRNA. Exemplary Cas13 enzymes are known in the art and include Cas13a (formerly C2c2), Cas13b, Cas13c, and Cas13d. In some embodiments, the Cas13a protein is Cas13a from Leptotrichia wadeii (i.e., LwaCas13a). In some embodiments, the Cas13a protein is Cas13a from Leptotrichia buccalis (i.e., LbuCas13a). In some embodiments, the Cas13b protein is Cas13b from Prevotella sp. MA2016 (i.e., PsmCasI 3b).

[0100] In some embodiments, the Cas nuclease is a Cas12 nuclease. Cas12 nucleases cleave DNA and exhibit collateral activity after recognition and cleavage of a target molecule, leading to non-specific degradation of any nearby DNA regardless of complementarity to the crRNA. Exemplary Cas12 enzymes are known in the art and include Cas12a (formerly Cpf1 ) and Cas12b (formerly C2c1 ). In some embodiments, the Cas12a protein is Cas12a from Lachnospiraceae bacterium ND2006 (i.e., LbaCas12a).

[0101] In some embodiments, the Cas nuclease is a Cas14 nuclease.

[0102] 2. crRNA

[0103] A crRNA is an oligonucleotide that specifically binds to a target nucleic acid (e.g., an APOL1 DNA or an APOL1 RNA) and is recognized or bound by a Cas nuclease. When complexed with a Cas nuclease and bound or hybridized to a target nucleic acid, the target nucleic acid is cleaved.

[0104] The crRNA includes a sequence that is complementary to a target region of an APOL1 nucleic acid (e.g., an APOL1 DNA or an APOL1 RNA). In some embodiments, the crRNA specifically binds to a G1 APOL1 variant. Exemplary crRNAs that bind specifically bind a G1 APOL1 variant may include a nucleic acid sequence of Table 1 (e.g., any one of crRNAI -crRNA9) or a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a nucleic acid sequence of Table 1 (e.g., any one of crRNAI -crRNA9). In some embodiments, any one of crRNAs 1 -9 may be used in conjunction with LwaCas13a.

[0105] Table 1. Exemplary crRNA sequences that specifically bind to G1 APOL1 variants

[0106] In some embodiments, the crRNA specifically binds to a G2 APOL1 variant. Exemplary crRNAs that bind specifically bind a G2 APOL1 variant may include a nucleic acid sequence of Table 2 (e.g., crRNA36 or crRNA37) or a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a nucleic acid sequence of Table 2 (e.g., crRNA36 or crRNA37). In some embodiments, crRNA36 or crRNA37 may be used in conjunction with LbaCas12a.

[0107] Table 2. Exemplary crRNA sequences that specifically bind to G2 APOL1 variants

[0108] In some embodiments, the crRNA specifically binds to wild-type GO APOL1 . Exemplary crRNAs that bind specifically bind wild-type GO APOL1 may include a nucleic acid sequence of Table 3 (e.g., any one of crRNA10-crRNA35 or crRNA38-66) or a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a nucleic acid sequence of Table 3 (e.g., any one of crRNA10-crRNA35 or crRNA38-crRNA66). crRNA10-crRNA35 and crRNA46-crRNA66 are useful for discriminating between the wild-type GO APOL1 and the G2 APOL1 variant. crRNA38-crRNA45 are useful for discriminating between the wild-type GO APOL1 and the G1 APOL1 variant. In some embodiments, any one of crRNAI 0-crRNA35 may be used in conjunction with PsmCasI 3b. In some embodiments, any one of crRNA38-crRNA45 may be used in conjunction with LbaCas12a. In some embodiments, any one of crRNA46-crRNA66 may be used in conjunction with LwaCas13a. Table 3. Exemplary crRNA sequences that bind to wild-type GO APOL1

[0109] 3. Reporter

[0110] In some embodiments, a reporter may include a fluorophore, a nucleic acid linker, and a quencher. Exemplary fluorophores include 5’ TEX615 (5TEX615), 5’ 6-FAM (56-FAM), 5’ Hexachlorofluorescein, and carboxyfluorescein. Exemplary nucleic acid linkers include TArArUGC, rUrUrUrUrU, rArArArArA, and TTATT, wherein “r” indicates the following nucleotide is an RNA nucleotide. Exemplary quenchers include 3IABkFQ and 3IAbRQSp. In some embodiments, the reporter includes 5TEX615 / TArArUGC / 3IAbRQSp, 56-FAM / rUrUrUrUrU / 3IABkFQ, 56-FAM / rArArArArA / 3IABkFQ, 5TEX615 / rArArArArA / 3IAbRQSp, 5 Hexachlorofluorescein / TTATT / 3IABkFQ, or RNASE ALERT™. RNASE ALERT™ includes the fluorophore carboxyfluorescein.

[0111] In some embodiments, a reporter may include a fluorophore, a nucleic acid linker, and a binding moiety. Exemplary fluorophores include 5’ 6-FAM (56-FAM). Exemplary nucleic acid linkers include UUUUUUUUUUUUUU (SEQ ID NO: 94) and TTATTATT. Exemplary binding moieties include biotin, digoxigenin, avidin, and NeutrAvidin™ biotin-binding protein. In some embodiments, the reporter includes 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ). In some embodiments, the reporter includes 56- FAM / TTATTATT / 3DigN. In some embodiments, the nucleic acid detection system further includes a cleaved reporter. Following hybridization of a crRNA to its target nucleic acid, the Cas nuclease undergoes cis-cleavage, cleaving the target nucleic acid. In some embodiments, sequence-specific binding and cis-cleavage activity then initiates trans-cleavage activity (i.e., multi-turnover activity) of the Cas nuclease, where transcleavage is indiscriminate and leads to non-sequence-specific cutting of nucleic acid molecules by the Cas nuclease, including the reporter molecule at the nucleic acid linker.

[0112] 4. Target nucleic acid

[0113] In some embodiments, the nucleic acid detection system further includes a target nucleic acid. A target nucleic acid is a sequence to which a crRNA is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization. A target sequence may include RNA polynucleotides. In some embodiments, the target nucleic acid is an APOL1 target DNA. In some embodiments, the target nucleic acid is an APOL1 target RNA. In some embodiments, the target nucleic acid may include a sequence corresponding to the G1 APOL1 variant. In some embodiments, the target nucleic acid may include a sequence corresponding to the G2 APOL1 variant. In some embodiments, the target nucleic acid may include a sequence corresponding to the GO wild-type APOL1 .

[0114] III. Lateral flow strips

[0115] The disclosure further provides lateral flow strips including a nucleic acid detection system disclosed herein, an application area, one or more capture areas, and a control area. Substrates suitable for use in lateral flow strip are known in the art. These may include, but are not limited to, membranes or pads made of cellulose and / or glass fiber, polyesters, nitrocellulose, or absorbent pads.

[0116] 1. Nucleic acid detection systems

[0117] In some embodiments, the lateral flow strip includes a nucleic acid detection system disclosed herein.

[0118] In some embodiments, the lateral flow strip is for genotyping of the APOL1 G1 variant. In this embodiment, the nucleic acid detection system includes (a) a first Cas nuclease (e.g., LwaCas13a) and a second Cas nuclease (e.g., LbaCas12a); (b) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid (e.g., any one of crRNAI -crRNA9 (e.g., crRNA5)) and a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid (e.g., any one of crRNA38-crRNA45 (e.g., crRNA41 )); and (c) a reporter cleavable by the first Cas nuclease (e.g., 56-FAM / UUUUUUUUUUUUUU / 3Bio, SEQ ID NO: 91 ) and a reporter cleavable by the second Cas nuclease (e.g., 56-FAM / TTATTATT / 3DigN). In some embodiments, the lateral flow strip for genotyping of the APOL1 G1 variant includes a nucleic acid detection system including (a) LwaCas13a and LbaCas12a; (b) crRNA5 and crRNA41 ; and (c) 56- FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN. In some embodiments, the nucleic acid detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved reporter (e.g., a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter).

[0119] In some embodiments, the lateral flow strip is for genotyping of the APOL1 G2 variant. In this embodiment, the nucleic acid detection system includes (a) a first Cas nuclease (e.g., LwaCas13a) and a second Cas nuclease (e.g., LbaCas12a); (b) a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid (e.g., any one of crRNA46-crRNA66 (e.g., crRNA62)) and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid (e.g., crRNA 36 or crRNA37 (e.g., crRNA36)); and (c) a reporter cleavable by the first Cas nuclease (e.g., 56-FAM / UUUUUUUUUUUUUU / 3Bio; SEQ ID NO: 91 ) and a reporter cleavable by the second Cas nuclease (e.g., 56-FAM / TTATTATT / 3DigN). In some embodiments, the lateral flow strip for genotyping of the APOL1 G2 variant includes a nucleic acid detection system including (a) LwaCas13a and LbaCas12a; (b) crRNA62 and crRNA36; and (c) 56- FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN. In some embodiments, the nucleic acid detection system further includes a target nucleic acid (e.g., an APOL1 target DNA or an APOL1 target RNA). In some embodiments, the nucleic acid detection system further includes a cleaved reporter (e.g., a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter).

[0120] 2. Application area

[0121] The nucleic acid detection system is added to the lateral flow substrate at an application area of the lateral flow strip, typically on one end of the lateral flow strip. In some embodiments, the application area includes nanoparticles. The nanoparticles may include a plasmon-resonance causing metal. Any suitable plasmon-resonance causing metal may be used, such as gold, silver, copper, titanium or chromium. In some embodiments, the nanoparticles include gold (AuNPs).

[0122] In some embodiments, the surface of the nanoparticle includes an antibody that binds the reporter. In some embodiments, the application area includes gold nanoparticles (AuNPs), wherein the surface of the nanoparticle includes an anti-Fam antibody (AuNPs).

[0123] 3. Capture area

[0124] The lateral flow strip further includes at least one capture area, typically a horizontal line running across the device. Each capture area includes an immobilized reagent. Exemplary immobilized reagents include streptavidin, anti-dioxigenin, avidin, and NeutrAvidin™ biotin-binding protein.

[0125] In some embodiments, a first binding agent (e.g., streptavidin) that specifically binds one reporter (e.g., biotin) is fixed or otherwise immobilized to the first capture region. The second capture region is located towards the opposite end of the lateral flow substrate from the first binding region. A second binding agent (e.g., anti-digoxigenin) that specifically binds another reporter (e.g., digoxigenin) is fixed or otherwise immobilized at the second capture region. In some embodiments, the lateral flow stick includes a first capture area including streptavidin and a second capture area including anti-digoxigenin.

[0126] 4. Control area

[0127] The lateral flow strip further includes a control area, which is an area on a lateral flow strip that is functionalized so that it will indicate that a sample has been applied to the lateral flow strip. In some embodiments, the control area includes an immobilized secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle (e.g., a secondary anti-species specific antibody that binds an anti-Fam antibody).

[0128] In some embodiments, upon application of the CRISPR detection system to the application area, reporter molecules carrying Fam and biotin or digoxigenin bind to anti-Fam gold nanoparticles (AuNPs), travel up the sticks, and bind to streptavidin or anti-digoxigenin capture areas, respectively. Intact reporter molecules carrying anti-FAM-AuNPs result in a purple color at the capture areas, while cleaved reporter molecules carrying anti-FAM-AuNPs travel further along the stick and bind to a secondary anti-species specific antibody in the control area, creating a purple control band. The absence of a purple test band (relative test band intensity below 0.5) indicates the positive detection of the target.

[0129] In some embodiments, the lateral flow strip for genotyping of the APOL1 G1 is used together with the lateral flow strip for genotyping of the APOL1 G2, which allows for discrimination between the six APOL1 genotypes (G0 / G0, G0 / G1 , G1 / G1 , G0 / G2, G1 / G2, and G2 / G2). Three distinct patterns on the lateral-flow sticks may be observed: wildtype samples result in the absence of the test band corresponding to wildtype (GO)-detecting systems; heterozygous samples resulted in the absence of both test bands; homozygous mutant samples resulted in the absence of the test band corresponding to mutant-systems.

[0130] II. Kit

[0131] In some aspects, the disclosure relates to kits including a nucleic acid detection system described herein or one or more lateral flow strips described herein. In some embodiments, the kit includes two lateral flow strips described herein (e.g., two different lateral flow strips described herein).

[0132] For example, in some embodiments, a kit includes a lateral flow strip for genotyping of the APOL1 G1 variant and a genotyping of the APOL1 G2 variant. Together, the two lateral flow strips allow for distinguishing between all six possible APOL1 genotypes (G0 / G0, G0 / G1 , G1 / G1 , G0 / G2, G1 / G2, G2 / G2).

[0133] 1. Poly nucleic acid isolation component

[0134] In some embodiments, a kit further includes a nucleic acid isolation component (e.g., genomic DNA isolation component) that can be used to isolate nucleic acids from a sample (e.g., a blood sample or a saliva sample).

[0135] 2. Amplification component

[0136] The kit may further include an amplification component that serves to amplify a target molecule (e.g., an APOL1 gene) prior to detection. An amplification component may include a polymerase and at least one primer.

[0137] In some embodiments, a polymerase is a DNA polymerase. Examples of DNA polymerases are known to those having ordinary skill in the art. In some embodiments, a polymerase is an RNA polymerase. Examples of RNA polymerases are known to those having ordinary skill in the art. In some embodiments, the RNA polymerase is T7 RNA polymerase. In some embodiments, amplification is performed using a recombinase polymerase amplification method (RPA), which uses a recombinase, a single-stranded DNA-binding protein and a stranddisplacing polymerase. When amplifying RNA, the RPA method can also include a reverse transcriptase to transcribe RNA to DNA for amplification (RT-RPA). Subsequent to amplification of nucleic acids in a sample by RPA or RT-RPA, T7 RNA polymerase (or another RNA polymerase) can be used to produce RNA for recognition and cleavage by a Cas13 nuclease.

[0138] In some embodiments, an amplification component includes a primer that facilitates amplification of a target molecule. In some embodiments, an amplification component includes multiple primers. For example, in some embodiments, an amplification component includes a primer pair (i.e., a forward and a reverse primer).

[0139] When a detection system includes a primer pair, the forward and reverse primer of the primer pair may be present in different concentrations. In some embodiments, the concentration of the reverse primer is greater than the concentration of the forward primer. For example, in some embodiments, the concentration of the reverse primer is 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, or 8 times higher than the concentration of the forward primer. In some embodiments, the forward and reverse primer concentrations are 120 nM and 480 nM, respectively.

[0140] In some embodiments, an amplification system includes a forward primer and a reverse primer that amplify an APOL1 nucleic acid. In some embodiments, the amplification system includes: a forward primer including a nucleic acid sequence of Table 4 (e.g., any one of F1 -F6, F8, and F9) or a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with a nucleic acid sequence of Table 4 (e.g., any one of F1 -F6, F8, and F9); and a reverse primer including a nucleic acid sequence of Table 5 (e.g., any one of R1 -R9) or a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with a nucleic acid sequence of Table 5 (e.g., any one of R1 -R9). In some embodiments, the amplification system includes a forward primer including the sequence of F9, and a reverse primer including the sequence of R7.

[0141] Table 4. Exemplary forward primers

[0142] Table 5. Exemplary reverse primers

[0143] III. Methods

[0144] In some aspects, the disclosure relates to methods of detecting a target APOL1 nucleic acid in a sample. These methods may utilize a nucleic acid detection system described herein, one or more lateral flow strips described herein, and / or a kit described herein.

[0145] In some embodiments, the sample is a blood sample. In some embodiments, the sample is a saliva sample.

[0146] In some embodiments, prior to contacting the sample with a nucleic acid detection system described herein, one or more lateral flow strips described herein, and / or a kit described herein, the method includes purifying nucleic acids from the sample; for example, to produce a sample including nucleic acid molecules.

[0147] In some embodiments, prior to contacting the sample with a nucleic acid detection system described herein, one or more lateral flow strips described herein, and / or a kit described herein, the method includes amplifying a target molecule; for example, using an isothermal recombinase polymerase amplification method (RPA), optionally followed by producing RNA using an RNA polymerase such as T7 RNA polymerase.

[0148] In some embodiments, the method for determining a subject’s APOL1 genotype includes: (a) providing an amplified blood sample or saliva sample from a subject; (b) incubating the amplified blood sample or saliva sample with a nucleic acid detection system described herein; and (c) detecting the reporter in said sample, thereby determining the subject’s APOL1 genotype. In some embodiments, the detecting includes measuring the fluorescence of the reporter. In some embodiments, the method for determining a subject’s APOL1 genotype includes: (a) providing an amplified blood sample or saliva sample from a subject; (b) incubating the amplified blood sample or saliva sample with a nucleic acid detection system described herein; (c) applying the reaction of step (b) to a lateral flow strip; and (d) detecting the reporter in the lateral flow strip, thereby determining the subject’s APOL1 genotype.

[0149] In some embodiments, the detecting includes determining the presence or absence of a band in the capture area of the lateral flow strip.

[0150] EXAMPLES

[0151] Table of Contents

[0152] Example 1. Materials and methods

[0153] Sample preparation

[0154] Brazil and USA patient cohort samples were prepared using the DNeasy Blood & Tissue kit (Qiagen), according to the manufacturer’s instructions. Germany patient cohort samples were prepared using either the Gentra Puregene Kit (Qiagen) or using magnetic beads and the QIAsymphony SP machine (Qiagen), according to the manufacturer’s instructions. DNA integrity was assessed by 260 / 280 ratio with a spectrophotometer (Nano-drop, ThermoFisher).

[0155] RPA primer design

[0156] Primers were designed using NCBI Primer-BLAST, with lengths of 25-30nt and a melting temperature of 57-67 °C. Combinations of primers were tested for their ability to amplify a synthetic DNA target resulting in amplicons that include both the G1 and G2 coordinates. The primers were designed such that the forward primer is at the 5’ end of the G1 and G2 coordinates, while the reverse primer is at their 3’ end. Forward primers contained a T7 promoter overhang so that amplified DNA could be converted to RNA by T7 transcription, allowing for subsequent detection by LwaCas13a and PsmCas13b.

[0157] Recombinase polymerase amplification (RPA) reaction

[0158] RPA was completed for 1 hour at 39°C at a volume of 20 pl, including 2 pl DNA as sample input, using either the TwistAmp Basic kit (TwistDx) or the multienzyme isothermal rapid amplification kit (AmpFuture biotech). RPA using the TwistAmp Basic kit was completed with the following modifications: pellets were diluted with rehydration buffer containing 120 nM forward primer, 480 nM reverse primer, and 8 mM MgAOc (final concentrations). RPA using the multienzyme isothermal rapid amplification kit was completed with the following modifications: per reaction, 0.4x of a pellet was used with 120 nM forward primer, 480 nM reverse primer, 12.5 pl Buffer A, 1 pl Buffer B.

[0159] LwaCas13a and PsmCas13b protein purification

[0160] The expression vectors pC013-Twinstrep-SUMO-huLwaCas13a (Addgene plasmid #9009, RRID: Addgene_90097, Gootenberg et al., Science 356, 438-442 (2017)) and pC0061 PsmCas13 (B05) His6- TwinStrep-SUMO-Bsal (Addgene plasmid #115211 , RRID:Addgene_115211 , Abudayyeh et al. Nature 550, 280-284 (2017)) were a gift from Feng Zhang. The Cas13a protein from Leptotrichia wade ii and the Cas13b protein from Prevotella sp. MA2016 were produced using E. coli 7 Express cells (NEB) cotransformed with the pRARE2 plasmid. TB media was supplemented with 100 pg / mL ampicillin and 34 pg / mL chloramphenicol. The cultures were grown at 37°C until the ODeoo reached about 2. Gene expression was induced by the addition of 0.5 mM isopropyl p-D-1 -thiogalactopyranoside at 17°C. After induction, cultures were grown overnight at 17°C. Cells were harvested by centrifugation and the pellets were stored at -80°C.

[0161] For purification, cells were resuspended in lysis buffer (50 mM Tris pH 8.0, 0.5 M KCI, 5 % glycerol, 1 mM MgCl2), supplemented with complete™ (EDTA-free protease inhibitor cocktail, Roche), 0.5 mM dithiothreitol (DTT), 1 mM phenylmethyl-sulfonyl fluoride, and 6.000 U / mL lysozyme (Serva), and lysed by sonication (SONOPULS HD 2200, Bandelin Electronic GmbH & Co. KG). The extract was cleared by centrifugation at 36.000xg and the His6-fusion protein was captured from the supernatant using affinity chromatography on a 5 mL Ni Sepharose® 6Fast Flow column (Cytiva), equilibrated with 50 mM Tris-HCI pH 8.0, 0.5 M KCI, 5 % glycerol, 1 mM MgCL, 5 mM imidazole pH 8.0, and 0.5 mM DTT. Before elution with elution buffer (20 mM Tris-HCI pH 8.0, 0.5 M KCI, 5 % glycerol, 0.5 mM DTT, 0.2 M imidazole pH 8.0), the bound protein was washed three times with various wash buffers (1 : 20 mM Tris- HCI pH 8.0, 1 M KCI, 5 % glycerol, 0.5 mM DTT, 5 mM imidazole pH 8.0; 2: 20 mM Tris-HCI pH 8.0, 0.5 M KCI, 5 % glycerol, 0.5 mM DTT, 5 mM imidazole pH 8.0; 3: 20 mM Tris-HCI pH 8.0, 0.5 M KCI, 5 % glycerol, 0.5 mM DTT, 15 mM imidazole pH 8.0) to remove contaminating nucleic acids and proteins. The eluted protein was supplemented with 5 % glycerol and 0.5 mM DTT, and the fusion tag was cleaved off by adding 1 :75 (w / w) yeast Ulpl p SUMO protease (produced in-house). The protein was further purified by ion exchange chromatography on a HiTrap Heparin HP column (Cytiva), equilibrated with 20 mM Hepes-NaOH pH 7.5, 0.25 M KCI, 5 % glycerol, and 1 mM DTT. The pooled fractions were supplemented with 5 mM MgCl2, concentrated and applied onto a 26 / 600 Superdex 200 prep grade column (Cytiva) equilibrated with 50 mM Tris-HCI pH 7.5, 1 M NaCI, and 1 mM DTT. The storage buffer of the protein was adjusted to 50 mM Tris-HCI pH 7.5, 600 mM NaCI, 5% Glycerol, and 2 mM DTT. The purified protein was flash-frozen in small aliquots with liquid nitrogen and stored at -80°C until further use. crRNA design crRNA constructs were designed so that synthesized LwaCas13a, PsmCas13b, and LbaCas12a crRNAs included spacers of length 28, 30, and 20 nucleotides, respectively, and are reverse complement to the target site. DNA oligos (Eurofins) with a T7 promoter sequence were used as constructs for in-vitro RNA transcription of the crRNAs. LwaCas13a and LbaCas12a constructs contained a direct repeat sequence at the 5’ end of the spacer, while PsmCasI 3b constructs contained a direct repeat at the 3’ end of the spacer.

[0162] Reporter molecules

[0163] For fluorescence-based readout, reporter molecules included sequences that were collaterally cleaved by each Cas enzyme (AU or UUUUU for LwaCas13a; AAAAA for PsmCasI 3b; TTATT for LbaCas12a). Reporter molecules included a quenched fluorophore, consisting of Texas red, Hex, or Fam and were ordered as RNA or ssDNA (IDT). Reporter molecules for lateral-flow based readout were designed similarly except with either biotin or digoxigenin instead of a quencher.

[0164] Production of crRNAs and target RNAs

[0165] Synthesis of RNA was completed using the HiScribe T7 Quick High Yield RNA Synthesis kit (New England Biolabs) according to the manufacturer's instructions and purified using either the Monarch RNA Cleanup Kit (50 pg, New England Biolabs) or the RNA Clean & Concentrator 25 (Zymo). RNA purity was measured using a spectrophotometer (Nano-drop; Thermofischer).

[0166] Fluorescence-based assay

[0167] 3 pL of RPA product was detected in a 20 pL CRISPR reaction in a 384-well microplate at 37°C with final concentrations of 250 nM poly-A-Texas Red reporter, 250 nM AU-Texas red reporter, 125 nM RNAse Alert, 40 U / pl murine RNAse inhibitor (NEB), 1 X NEB buffer 2, 4 mM rNTPs, 1 .5 U / pl T7 RNA polymerase. Cas enzyme:crRNA ratios were kept at 2:1 . Fluorescence was measured on a multi-mode microplate reader; iD5 (Germany and USA cohorts) or iD3 (Brazil cohort) for three different excitation / emission wavelength pairs (485 / 525 nm for Fam; 530 / 570 nm for Hex, and 585 / 625 nm for Texas red). Fluorescence was measured for at least 1 hour at 5-minute intervals.

[0168] Lateral-flow-based assay

[0169] Lateral-flow-based detection was performed as described for the fluorescence-based assay, with the following modifications. G1 detection reactions were performed with 90 nM LwaCas13a, 360 nM LbaCas12a, 45 nM LwaCas13a crRNA, 180 nM LbaCas12a crRNA, 2 mM rNTPs, 5 nM for each Biotin- Fam reporter and Digoxigenin-Fam reporter (final concentrations). G2 detection reactions were performed with 90 nM LwaCas13a, 180 nM LbaCas12a, 45 nM LwaCasI 3a crRNA, 90 nM LbaCasI 2a crRNA, 5 nM for each Biotin-Fam reporter and Digoxigenin-Fam reporter (final concentrations). The T7 RNA transcription and CRISPR reactions were completed on a heat block for 1 hour at 37°C. 20 pl CRISPR reactions were mixed with 80 pl assay buffer followed by insertion of the lateral-flow sticks (Hybridetect 2T, Milenia Biotec) and incubation for 10 min at room temperature.

[0170] Patient populations & Ethics

[0171] Clinical samples from different sites were obtained. In Brazil, institutional review board approval was obtained from the National Committee for Ethics in Research (Brasilia, Brazil). Written informed consent was acquired from all participants. Blood samples were collected in EDTA tubes and kept at 20 °C until DNA extraction. Additional samples were obtained from discarded material from adults (>18 years) presenting to Massachusetts General Hospital. The material was excess to clinical needs, and selected based on having race documented in the Electronic Health Record as “Black or African American” and an estimated glomerular filtration rate (eGFR, as calculated with the CKD-EPI refit 2021 creatinine-based equation) below 45 mL / min / 1 .73m2. Whole blood samples were frozen at -80 °C before research use. The study was granted exemption from informed consent due to the use of anonymized discarded clinical samples and was approved by the Mass General Brigham IRB, Protocol no. 2022P000747.

[0172] Samples were also collected from patients presenting to the Neurology department at the University Hospital rechts der Isar (Technical University Munich (TUM)) after informed consent, and stored in their Biobank which operates under 9 / 15-S at the local ethics committee (Ethikkommission der Technischen Universitat Munchen).

[0173] Genotyping of patient samples

[0174] The samples of the USA cohort were genotyped for the APOL1 G1 and G2 variants using quantitative real-time PCR (qPCR). For this, samples were diluted to 20 ng / pl. The qPCR assay consisted of 2 reactions, with 2 sets of TaqMan probes in each reaction. The G1 assay has 1 probe complementary to the G1 site and another complementary to the GO sequence at the same single nucleotide variant coordinate. Similarly, for the G2 assay, 1 probe detects the G2 sequence and another detects the GO sequence at the same coordinates of the 6 base pair deletion. Each probe is tagged with a different fluorophore. Each assay plate run included human positive controls for the combination of genotypes: G0 / G0, G0 / G1 , G0 / G2, G1 / G1 , G2 / G1 , G2 / G2, assayed with both G1 and G2 TaqMan probes. Amplification results were interpreted with the QuantStudio Real-Time PCR Software V1 .2 (Applied Biosystems, Foster City, CA). The samples of the Brazil and Germany cohorts were genotyped by Sanger Sequencing (Eurofins). Samples were first amplified by PCR. The PCR products were then purified using a PCR purification kit as per the manufacturer’s instructions (Qiagen).

[0175] Calculation of genotype scores

[0176] For calculating the genotype score when detecting gDNA, the slope of the resulting background subtracted fluorescence data (RFUs) was calculated for consecutive fluorescence measurements between five and 60 minutes. The maximum slope for each replicate was then normalized to the mean maximum slope for an on-target synthetic standard (sG1 G1 for LwaCas13a and PsmCas13b, and sG2G2 for LbaCas12a). Four replicates were tested for each gDNA sample such that experimental variance would be assessed. No data was excluded.

[0177] Machine learning model

[0178] We performed multivariate time-series classification using the sktime library (East-Seletsky et al. Nature 538, 270-273 (2016)). One multivariate time trace consists of time traces for the three enzymes, and traces were split randomly into 70% training and 30% validation set per genotype. We used a Canonical Interval Forest with 40 estimators (East-Seletsky et al. Nature 538, 270-273 (2016)), and estimated the accuracy of the classifier by doing 100 random splits into training and validation sets and then taking the average classification accuracy. We did not observe increased accuracy when performing data augmentation or class balancing (Kaminski et al. Nat Biomed Eng 5, 643-656 (2021 )).

[0179] Image analysis of lateral-flow reactions Using Imaged software (National Institutes of Health), the relative band intensity was calculated. Images were first converted to 8 bit and inverted, and then the region of the band was highlighted and its mean gray value was measured. For G1 mutant and G1 wt detection, the relative band intensities were calculated as the anti-streptavidin or digoxigenin bands, respectively, divided by the control bands. For G2 mutant and G2 wt detection, the relative band intensities were calculated as the anti-digoxigenin or streptavidin bands, respectively, divided by the control band.

[0180] Nucleic acid sequences

[0181] Nucleic acid sequences are provided in Table 6. Single stranded DNA constructs (SEQ ID NOs: 95-160) for crRNAs include a T7 promoter sequence to enable in-vitro RNA transcription of the crRNAs. A T7 promoter sequence may be added to any single stranded DNA construct as desired.

[0182] Table 6. Nucleic acid sequences

[0183] Statistics

[0184] Statistical analyses were performed using GraphPadPrism software. Gaussian distribution was assumed when performing t-tests, and groups were assigned as unpaired and assumed to have the same standard deviations.

[0185] P values are provided in Table 7.

[0186] Table 7. P values

[0187] Example 2. crRNA optimization for the rapid detection of AP0L1 risk variants.

[0188] First, the targets of the genotyping assay were defined. G1 codes for two amino acid substitutions, G342 and M384 [dbSNP (Single Nucleotide Polymorphism Database) numbers rs73885319 and rs60910145] (Friedman et al., Annu. Rev. Physiol. 82, 323-342 (2020)). These SNPs are in almost perfect linkage disequilibrium, but approximately 1 % of haplotypes with the G342 allele do not contain the M384 allele (Egbuna et al., N. Engl. J. Med. 388, 969-979 (2023)). However, the risk of disease in cases where the G342 allele is present but not M384 is believed to be the same as when both alleles are present. Therefore, testing for G342 only is considered acceptable when assessing disease risk associated with the G1 variants (Friedman et al., Annu. Rev. Physiol. 82, 323-342 (2020), Kopp et al., J. Am. Soc. Nephrol. 22, 2129-2137 (2011 ), Thomson et al., Proc. Natl. Acad. Sci. U. S. A. 111 , E2130-9 (2014)). Thus, the A:G SNP rs73885319 was detected for the G1 variant. The second variant associated with kidney disease and detected in our assay, G2 (rs71785313), is a six-base-pair (TTATAA) deletion that results in the loss of the amino acid residues 388N and 389Y (Friedman et al., Annu. Rev. Physiol. 82, 323-342 (2020)).

[0189] To identify crRNAs to detect the APOL1 G1 and G2 variants, screens were performed by systematically exploring the effect of the spacer sequence and position. crRNAs for LwaCas13a and PsmCas13b were tested for their ability to discriminate between on and off-target synthetic RNA targets (Fig. 1) Nine LwaCas13a G1 sensing crRNAs were designed such that the A:G SNP was placed at position 3 of the spacer sequence, and either one or two synthetic mismatches were introduced to increase specificity (Fig. 1a). The resulting signal intensities were greatly affected by the positioning and number of synthetic mismatches, and a crRNA was identified with two synthetic mismatches at positions one and four showing the highest on-to-off target signal intensity ratios (crRNA 5, Fig. 1b). To genotype for the G2 variant, 26 PsmCas13b crRNAs complementary to the wildtype sequence (TTATAA) were designed, with adjacent spacers differing by one base (Fig. 1c). While the 6 base pair deletion (delTTATAA) resulted in low off-target signal intensities for most crRNAs tested, a large variance in the on-target signal intensities was observed depending on the spacer design (Fig. 1d). Nine successive crRNAs (crRNAs 16-24) each resulted in a relative on-target signal intensity greater than 10, while the remaining crRNAs resulted in a reduced on-target signal intensity. The best performing crRNA 22 was selected for further experiments.

[0190] Example 3. Optimization of RPA design for isothermal amplification.

[0191] The RPA reaction was optimized to enable isothermal preamplification of genomic DNA (gDNA) to a concentration detectable by the Cas-crRNA complexes. Primer combinations that would generate amplicons containing either the G1 SNP (Fig. 2a) or the G2 six base pair deletion (Fig. 2b) were tested. Nine primer pairs were designed for each variant and tested for their ability to amplify DNA standards at either 1 pM or 10 fM. While five of nine G1 primer pairs robustly amplified the 10 fM DNA target (Fig. 2a), only one G2 primer pair (F5R5) resulted in efficient amplification of both the 10 fM and 1 pM targets, albeit at lower signal intensities (Fig. 2b). To enable a multiplexed assay for simultaneous genotyping of both G1 and G2, the inventors hypothesized that achieving equally efficient amplification of both regions would be advantageous for generating equimolar amounts of RNA for CRISPR detection. Therefore, it was tested whether a single amplicon covering both variants could be generated (Fig. 2c). Elongating the amplicon did not reduce RPA efficiency, and two primer pairs were identified that robustly amplified both variants (F1 R7 and F9R7) at 1 pM or 10 fM where F9R7 showed the highest signal intensity (Fig. 2c). Different forward and reverse primer concentrations were then tested (Fig. 2d) and a reverse primer concentration of 480 nM resulted in the most efficient amplification, and forward / reverse primer concentrations of 120 / 480 nM were selected for our assay.

[0192] Example 4. Comparison of APOL1 genotyping on synthetic and genomic DNA.

[0193] To evaluate the capability to detect DNA targets in a multiplexed assay, the previously identified RPA primers and crRNAs sensing G1 mutant (LwaCas13a) and G2 wildtype (PsmCas13b) were included. The collateral cleavage activity of both LwaCas13a and PsmCas13b was simultaneously measured by using two RNA oligonucleotides (Gootenberg et al., Science 0179, 1 -10 (2018)) containing a red and green fluorescent dye (Texas Red and 6-Carboxyfluorescein (6-FAM), respectively) that indicate orthogonal collateral cleavage preferences of these two Cas enzymes. The ability of the assay to detect and discriminate between synthetic DNA at 1 pM that mimicked three APOL1 genotypes: G2G2, G1G2, G1 G1 was tested (Fig. 3a-b). LwaCas13a and PsmCas13b both resulted in the highest signal intensity for the detection of the synthetic G1 G1 (sG1 G1 ) target, which is on-target for both enzymes. This was followed by a medium signal intensity for heterozygous sG1 G2, and the lowest signal intensity, similar to the non-template control (NTC), for the detection of the off-target sG2G2. It was next assessed if the ability to detect and discriminate between the synthetic DNA targets could be extended to gDNA isolated from human blood (Fig. 3c-d). Similarly to synthetic DNA targets, LwaCas13a could correctly discriminate all possible G1 variants (Fig. 3c). In contrast, PsmCas13b did not enable discrimination of wildtype and heterozygous human gDNA samples (Fig. 3d). Specifically, G2 heterozygous samples with the genotypes G0G2 and G1 G2 resulted in a fluorescence signal indistinguishable from the G2 wildtype samples G0G1 and G1 G1 .

[0194] To improve G2 genotyping on human gDNA, a third enzyme (LbaCas12a) was incorporated to facilitate the detection of alleles containing the G2 deletion. Thereby, distinguishing between on-target and heterozygous samples for the G2 variant would no longer be necessary for PsmCasI 3b. Instead, signal intensities would be classified as either low for off-target detection or high for both on-target and heterozygous detection. Unlike LwaCas13a and PsmCasI 3b, LbaCas12a relies on a protospacer adjacent motif (PAM) to enable target recognition. In addition to its canonical TTTV-PAM, numerous non- canonical PAMs such as TCTV, TTCV, and CTTV have been reported (Chen et al., Genome Biol / 21 . 78 (2020), Zhou et al., Mol. Ther. 30, 244-255 (2022)). Since there was no canonical TTTV-PAM in proximity to the G2 deletion, crRNAs were designed that utilize non-canonical PAMs (Fig. 3e) and explored two different strategies for positioning of the G2 deletion: one within the spacer (crRNA 36) and the other within a CTTA-PAM (crRNA 37). crRNA 36 resulted in a greater ability to discriminate between on-target and off-target synthetic DNA (Fig. 3f) and was selected as G2 mutant sensing crRNA (LbaCas12a) for analysis of human gDNA.

[0195] Example 5. Multiplexed CRISPR-genotyping for detection of two APOL1 variants comprising six genotypes

[0196] To multiplex LwaCas13a, PsmCasI 3b, and LbaCas12a in one assay, the orthogonal cleavage of six reporter oligonucleotides was evaluated, differing in sequence and fluorophore-quencher combinations (Fig. 4a). For each reporter molecule, the resulting signal intensity for each enzyme was measured when detecting an on-target standard. Commercially available RNAse Alert and AAAAA-Texas Red were chosen as RNA reporter molecules for LwaCas13a and PsmCasI 3b, respectively, and TTATT- Hexachlorofluorescein (HEX) was selected as the DNA reporter molecule for LbaCas12a.

[0197] Utilizing the optimum crRNAs, primers, and reporter molecules, it was tested whether the 6 APOL1 genotypes could be accurately discriminated between (Fig. 4b). Synthetic DNA mimicking the different genotypes were first used. LwaCas13a (Fig. 4c, upper panel) correctly discriminated all G1 variants showing the highest signal intensity for on-target (sG1 G1 ), followed by a medium signal intensity for heterozygous (sG0G1 , sG1 G2), and the lowest signal intensity for off-target (sGOGO, sG0G2, sG2G2). LbaCas12a (Fig. 4c, middle panel) correctly identified G2 deletions, whereby on-target and heterozygous variants (sG0G2, sG1 G2, sG2G2) resulted in a higher signal intensity as compared to off- targets (sGOGO, sG0G1 , sG1 G1 ). Vice versa, PsmCasI 3b (Fig. 4c, lower panel) correctly identified G2 wt sequences with on-target and heterozygous variants (sGOGO, sG0G1 , sG0G2, sG1 G2, sG1 G1 ) resulting in higher signal intensities as compared to off-targets (sG2G2).

[0198] The ability of the multiplexed assay to genotype gDNA samples isolated from human blood was next evaluated (Fig. 4d). While the assay accurately identified all human gDNA samples, similar to the results with synthetic DNA, variations in signal intensities were observed across different days and plate readers, making result interpretation challenging. To address this, synthetic on-target DNA standards were included alongside patient samples for data normalization. This enabled the calculation of a score for each genotype by dividing the maximum slope of a patient sample, measured between background subtracted RFUs from 5 to 60 minutes, by the maximum slope of the synthetic standard (Fig. 4e). Example 6. CRISPR-based AP0L1 genotyping in a multi-center patient cohort.

[0199] The CRISPR-genotyping assay was assessed by testing 124 patient samples from three cohorts (Germany, USA, Brazil) (Fig. 5). As a control, blood-derived gDNA was genotyped for the APOL1 variants by PCR and Sanger sequencing, representing the current gold standard in clinical routine. CRISPR-genotyping was performed blinded and genotypes were assigned based on signal intensities in the Fam, Texas Red, and Hex channels, with a unique combination representing each of the APOL1 genotypes (Fig. 5a). Genotype score thresholds were defined that allowed wild-type, heterozygous and homozygous G1 and G2 variants to be distinguished (Fig. 5b). For LwaCas13a detection, a score below 0.2 represents wildtype, a score between 0.2 and 0.8 represents heterozygous, and a score above 0.8 represents homozygous for the G1 SNP. A score below 0.05 for PsmCas13b or LbaCas12a represents homozygous or wildtype for the G2 deletion, respectively. As an integrated quality control for successful target amplification and detection, samples were classified with genotype scores below the lowest respective thresholds or that did not result in a signal intensity combination corresponding to an APOL1 genotype as invalid. Overall, the assay achieved an accuracy of 97.9% as compared to the gold standard method (Fig. 6).

[0200] To assess the assay's reproducibility under various conditions, including sample processing methods, assay reagents, operators, and read-out technologies, measurements were conducted on a subset of the samples at a different clinical center (Fig. 7). The genotype score method also resulted in correct discrimination of the six genotypes with high accuracy. However, for LwaCas13a-based G1 detection, the genotype scores were generally higher which required readjustments of the thresholds. To further enhance the simplicity and robustness of our analysis, a machine learning model was developed for multivariate time series classification (Fig. 5c). Utilizing this model to analyze the data from the 124 samples across both test centers, the assay resulted in an accuracy of 100 %, validating its precision for APOL1 genotyping (Fig. 5d).

[0201] Example 7. Multi-analyte lateral-flow readout of multiplexed CRISPR-genotyping.

[0202] This example is directed to optimizing toward a lateral-flow-based readout, enabling genotyping at the point-of-care. To enable the simultaneous detection of two analytes, lateral-flow sticks were used containing both a streptavidin and an anti-digoxigenin test band. Two multiplexed assays for G1 and G2 genotyping were designed (Fig. 8a). Each assay contained LwaCas13a-crRNA and LbaCas12a- crRNA complexes, and their respective biotin and digoxigenin-labeled reporter oligonucleotides. These reporter molecules additionally contained Fam, binding to anti-Fam gold nanoparticles (AuNPs) in the application area of the lateral flow sticks. Upon application of the CRISPR reaction product, reporter molecules carrying biotin and digoxigenin, travel up the sticks and bind to streptavidin or anti-digoxigenin test bands, respectively. Intact reporter molecules carrying anti-FAM-AuNPs result in a purple color at the test bands, while cleaved reporter molecules carrying anti-FAM-AuNPs travel further along the stick and bind to a secondary anti-species specific antibody creating a purple control band. The assays were designed such that the absence of a purple test band (relative test band intensity below 0.5) indicated the positive detection of the target. By utilizing low concentrations of reporter molecules (5 nM), collateral cleavage activity upon target detection effectively reduced intact reporter molecules sufficiently to prevent the formation of a purple test band.

[0203] For the G1 assay, the previously optimized G1 mutant sensing LwaCas13a crRNA (crRNA 5) was included and a G1 wildtype sensing LbaCas12a crRNA. To overcome the absence of canonical TTTV PAMs for Cas12a near the G1 SNP, we tested non-canonical C and T-rich PAMs (Fig. 9a). A highly discriminative crRNA (crRNA 41 ) was identified which resulted in a normalized signal intensity that was 4.6 times greater for on-target detection versus off-target detection (Fig. 9b). For the G2 assay, the previously optimized mutant sensing LbaCas12a crRNA (crRNA 36) was used and different G2 wildtype sensing LwaCas13a crRNAs were tested, selecting a crRNA (crRNA 62) with an on:off-target signal intensity ratio of 26.8. (Fig. 9c, d).

[0204] Subsequently, the ability to discriminate the six APOL1 genotypes was tested (Fig. 8b). Regarding both the G1 and G2 variants, three distinct patterns were observed on the respective lateralflow sticks: wildtype samples resulted in the absence of the test band corresponding to wildtype-detecting Cas-crRNA complexes; heterozygous samples resulted in the absence of both test bands; homozygous mutant samples resulted in the absence of the test band corresponding to mutant-detecting Cas-crRNA complexes. Considering both G1 and G2 assays, each APOL1 genotype produced a distinct test-band pattern observable visually without the need for additional equipment (Fig. 8b).

[0205] OTHER EMBODIMENTS

[0206] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.

[0207] All publications, patents, and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

[0208] Some embodiments of the technology described herein can be defined according to any of the following numbered embodiments:

[0209] E1 . A nucleic acid detection system comprising: (a) a Cas nuclease; (b) a crRNA that specifically binds to an APOL1 target nucleic acid; and (c) a reporter cleavable by the Cas nuclease.

[0210] E2. The nucleic acid detection system of E1 , wherein the Cas nuclease is a Cas13 nuclease.

[0211] E3. The nucleic acid detection system of E2, wherein the Cas13 nuclease is LwaCas13a.

[0212] E4. The nucleic acid detection system of E2, wherein the Cas13 nuclease is PsmCas13b.

[0213] E5. The nucleic acid detection system of E1 , wherein the Cas nuclease is a Cas12 nuclease.

[0214] E6. The nucleic acid detection system of E5, wherein the Cas12 nuclease is LbaCas12a.

[0215] E7. The nucleic acid detection system of any one of E1 -E6, wherein the crRNA specifically binds to a G1 variant APOL1 nucleic acid.

[0216] E8. The nucleic acid detection system of E7, wherein the crRNA comprises the nucleic acid sequence of any one of crRNAI -crRNA9. E9. The nucleic acid detection system of any one of E1 -E6, wherein the crRNA specifically binds to a G2 variant APOL1 nucleic acid.

[0217] E10. The nucleic acid detection system of E9, wherein the crRNA comprises the nucleic acid sequence of crRNA36 or crRNA37.

[0218] E11 . The nucleic acid detection system of any one of E1 -E6, wherein the crRNA specifically binds to a GO wild-type APOL1 nucleic acid.

[0219] E12. The nucleic acid detection system of E1 1 , wherein the crRNA comprises the nucleic acid sequence of any one of crRNAI 0-crRNA35.

[0220] E13. The nucleic acid detection system of E1 1 , wherein the crRNA comprises the nucleic acid sequence of any one of crRNA38-crRNA45.

[0221] E14. The nucleic acid detection system of E1 1 , wherein the crRNA comprises the nucleic acid sequence of any one of crRNA46-crRNA66.

[0222] E15. The nucleic acid detection system of any one of E1 -E14, wherein the ratio of Cas nuclease: crRNA is about 2:1 .

[0223] E16. The nucleic acid detection system of any one of E1 -E15, wherein the reporter comprises a fluorophore, a nucleic acid linker, and a quencher.

[0224] E17. The nucleic acid detection system of E16, wherein the reporter comprises

[0225] 5TEX615 / TArArUGC / 3IAbRQSp, 56-FAM / rUrUrUrUrU / 3IABkFQ, 56-FAM / rArArArArA / 3IABkFQ, 5TEX615 / rArArArArA / 3IAbRQSp, 5 Hexachlorofluorescein / TTATT / 3IABkFQ, or carboxyfluorescein / nucleic acid linker / quencher.

[0226] E18. The nucleic acid detection system of any one of E1 -E15, wherein the reporter comprises a fluorophore, a nucleic acid linker, and a binding moiety.

[0227] E19. The nucleic acid detection system of E18, wherein the binding moiety is biotin or digoxigenin.

[0228] E20. The nucleic acid detection system of E19, wherein the reporter comprises 56-

[0229] FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) or 56-FAM / TTATTATT / 3DigN.

[0230] E21 . The nucleic acid detection system of any one of E1 -E20, further comprising an APOL1 target DNA.

[0231] E22. The nucleic acid detection system of any one of E1 -E21 , further comprising an APOL1 target RNA.

[0232] E23. The nucleic acid detection system of E21 or E22, further comprising a cleaved reporter.

[0233] E24. The nucleic acid detection system of any one of E1 -E23, comprising: (a) LwaCas13a; (b) crRNA5; and (c) carboxyfluorescein / nucleic acid linker / quencher.

[0234] E25. The nucleic acid detection system of any one of E1 -E23, comprising: (a) PsmCas13b; (b) crRNA22; and (c) 5TEX615 / rArArArArA / 3IAbRQSp.

[0235] E26. The nucleic acid detection system of any one of E1 -E23, comprising: (a) LbaCas12a; (b) crRNA36; and (c) Hexachlorofluorescein / TTATT / 3IABkFQ.

[0236] E27. The nucleic acid detection system of any one of E1 -E23, comprising: (a) a first Cas nuclease, a second Cas nuclease, and a third Cas nuclease; (b) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid, a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid, and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid; and (c) a reporter cleavable by the first Cas nuclease, a reporter cleavable by the second Cas nuclease, and a reporter cleavable by the third Cas nuclease.

[0237] E28. The nucleic acid detection system of E27, wherein each Cas nuclease is a different Cas nuclease.

[0238] E29. The nucleic acid detection system of any one of E24-R28, further comprising a cleaved reporter.

[0239] E30. The nucleic acid detection system of any one of E27-R29, comprising: (a) LwaCas13a,

[0240] PsmCas13b, and LbaCas12a; (b) crRNA5, crRNA22, and crRNA36; and (c) carboxyfluorescein / nucleic acid linker / quencher, 5TEX615 / rArArArArA / 3IAbRQSp, and Hexachlorofluorescein / TTATT / 3IABkFQ.

[0241] E31 . The nucleic acid detection system of E30, further comprising a cleaved carboxyfluorescein / nucleic acid linker / quencher reporter, a cleaved 5TEX615 / rArArArArA / 3IAbRQSp reporter, or a cleaved Hexachlorofluorescein / TTATT / 3IABkFQ reporter.

[0242] E32. The nucleic acid detection system of any one of E1 -E23, comprising: (a) a first Cas nuclease and a second Cas nuclease; (b) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid and a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid; and (c) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease.

[0243] E33. The nucleic acid detection system of E32, wherein each Cas nuclease is a different Cas nuclease.

[0244] E34. The nucleic acid detection system of E32 or E33, further comprising a cleaved reporter.

[0245] E35. The nucleic acid detection system of any one of E32-E34, comprising: (a) LwaCas13a and

[0246] LbaCas12a; (b) crRNA5 and crRNA41 ; and (c) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN.

[0247] E36. The nucleic acid detection system of E35, further comprising a cleaved 56- FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

[0248] E37. The nucleic acid detection system of any one of E1 -E23, comprising: (a) a first Cas nuclease and a second Cas nuclease; (b) a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid; and (c) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease.

[0249] E38. The nucleic acid detection system of E37, wherein each Cas nuclease is a different Cas nuclease.

[0250] E39. The nucleic acid detection system of E37 or E38, further comprising a cleaved reporter.

[0251] E40. The nucleic acid detection system of Eany one of E37-E39, comprising: (a) LwaCas13a and

[0252] LbaCas12a; (b) crRNA62 and crRNA36; and (c) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN.

[0253] E41 . The nucleic acid detection system of E40, further comprising a cleaved 56- FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

[0254] E42. A lateral flow strip comprising: (a) the nucleic acid detection system of any one of E1 -E41 ; (b) an application area; (c) one or more capture areas comprising an immobilized reagent; and (d) a control area. E43. The lateral flow strip of E42, wherein the application area comprises nanoparticles comprising a plasmon-resonance causing metal, wherein the surface of the nanoparticle comprises an antibody that binds the reporter.

[0255] E44. The lateral flow strip of E43, wherein the plasmon-resonance causing metal comprises gold.

[0256] E45. The lateral flow strip of E43 or E44, wherein the surface of the nanoparticle comprises an anti¬

[0257] Fam antibody.

[0258] E46. The lateral flow strip of any one of E43-E45, wherein the control area comprises a secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle.

[0259] E47. The lateral flow strip of E46, wherein the control area comprises a secondary anti-species specific antibody that binds the anti-Fam antibody.

[0260] E48. The lateral flow strip of any one of E42-E47, comprising a first capture area that comprises streptavidin and a second capture area that comprises anti-digoxigenin.

[0261] E49. The lateral flow strip of any one of E42-E48, comprising: (a) a nucleic acid detection system comprising: (i) a first Cas nuclease and a second Cas nuclease; (ii) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid and a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid; and (iii) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease; (b) an application area comprising nanoparticles comprising a plasmon-resonance causing metal, wherein the surface of the nanoparticle comprises an antibody that binds the reporter; (c) a capture area comprising a first immobilized reagent; (d) a capture area comprising a second immobilized reagent; and (e) a control area comprising a secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle.

[0262] E50. The lateral flow strip of E49, wherein each Cas nuclease is a different Cas nuclease.

[0263] E51 . The lateral flow strip of E49 or E50, wherein the nucleic acid detection system further comprises a cleaved reporter.

[0264] E52. The lateral flow strip of any one of E42-E51 , comprising: (a) a nucleic acid detection system comprising: (i) LwaCas13a and LbaCas12a; (ii) crRNA5 and crRNA41 ; and (iii) 56- FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN; (b) an application area comprising anti-Fam gold nanoparticles (AuNPs); (c) a capture area comprising streptavidin; (d) a capture area comprising anti-digoxigenin; and (e) a control area comprising a secondary anti-species specific antibody that binds AuNPs.

[0265] E53. The lateral flow strip of E52, wherein the nucleic acid detection system further comprises a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

[0266] E54. The lateral flow strip of any one of E42-E48, comprising: (a) a nucleic acid detection system comprising: (i) a first Cas nuclease and a second Cas nuclease; (ii) a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid; and (iii) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease; (b) an application area comprising nanoparticles comprising a plasmon-resonance causing metal, wherein the surface of the nanoparticle comprises an antibody that binds the reporter; (c) a capture area comprising a first immobilized reagent; (d) a capture area comprising a second immobilized reagent; and (e) a control area comprising a secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle.

[0267] E55. The lateral flow strip of E54, wherein each Cas nuclease is a different Cas nuclease.

[0268] E56. The lateral flow strip of E54 or E55, wherein the nucleic acid detection system further comprises a cleaved reporter.

[0269] E57. The lateral flow strip of any one of E54-E56, comprising: (a) a nucleic acid detection system comprising: (i) LwaCas13a and LbaCas12a; (ii) crRNA62 and crRNA36; and (iii) 56- FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN; (b) an application area comprising anti-Fam gold nanoparticles (AuNPs); (c) a capture area comprising streptavidin; (d) a capture area comprising anti-digoxigenin; and (e) a control area comprising a secondary anti-species specific antibody that binds AuNPs.

[0270] E58. The lateral flow strip of E57, wherein the nucleic acid detection system further comprises a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

[0271] E59. A kit comprising one or more of the nucleic acid detection system of any one of E1 -E41 .

[0272] E60. A kit comprising one or more of the lateral flow strips any one of E42-E58.

[0273] E61 . The kit of E59, comprising the lateral flow strip of any one of E48-53 and the lateral flow strip of any one of E54-E58.

[0274] E62. The kit of any one of E59-E61 , further comprising a genomic DNA isolation component.

[0275] E63. The kit of any one of E59-E62, further comprising an amplification component.

[0276] E64. The kit of E63, wherein the amplification component comprises a DNA polymerase, a forward primer comprising the sequence of F9, and a reverse primer comprising the sequence of R7.

[0277] E65. A method for determining a subject’s APOL1 genotype, comprising contacting a sample from the subject with the nucleic acid detection system of any one of E1 -E41 , the lateral flow strip of any one of E42-E58, or the kit of any one of E59-E63.

[0278] E66. The method of E65, wherein the sample is a blood sample or a saliva sample.

[0279] E67. The method of E66, wherein the genomic DNA of the sample is purified.

[0280] E68. The method of E66 or E67, wherein the genomic DNA of the sample is amplified.

[0281] E69. A method for determining a subject’s APOL1 genotype, comprising: (a) providing an amplified blood sample from a subject; (b) incubating the amplified blood sample with the nucleic acid detection system of any one of E1 -E41 ; and (c) detecting the reporter in said sample, thereby determining the subject’s APOL1 genotype.

[0282] E70. The method of E69, wherein the detecting comprises measuring the fluorescence of the reporter.

[0283] E71 . A method for determining a subject’s APOL1 genotype, comprising: (a) providing an amplified blood sample from a subject; (b) incubating the amplified blood sample with the nucleic acid detection system of any one of E1 -E41 ; (c) applying the reaction of step (b) to a lateral flow strip; and (d) detecting the reporter in the lateral flow strip, thereby determining the subject’s APOL1 genotype.

[0284] E72. The method of E71 , wherein the detecting comprises determining the presence or absence of a band in the capture area of the lateral flow strip. Other embodiments are within the following claims.

Claims

CLAIMS1 . A nucleic acid detection system comprising:(a) a Cas nuclease;(b) a crRNA that specifically binds to an APOL1 target nucleic acid; and(c) a reporter cleavable by the Cas nuclease.

2. The nucleic acid detection system of claim 1 , wherein the Cas nuclease is a Cas13 nuclease.

3. The nucleic acid detection system of claim 2, wherein the Cas13 nuclease is LwaCas13a.

4. The nucleic acid detection system of claim 2, wherein the Cas13 nuclease is PsmCas13b.

5. The nucleic acid detection system of claim 1 , wherein the Cas nuclease is a Cas12 nuclease.

6. The nucleic acid detection system of claim 5, wherein the Cas12 nuclease is LbaCas12a.

7. The nucleic acid detection system of claim 1 , wherein the crRNA specifically binds to a G1 variantAPOL1 nucleic acid.

8. The nucleic acid detection system of claim 7, wherein the crRNA comprises the nucleic acid sequence of any one of crRNAI -crRNA9.

9. The nucleic acid detection system of claim 1 , wherein the crRNA specifically binds to a G2 variant APOL1 nucleic acid.

10. The nucleic acid detection system of claim 9, wherein the crRNA comprises the nucleic acid sequence of crRNA36 or crRNA37.11 . The nucleic acid detection system of claim 1 , wherein the crRNA specifically binds to a GO wild-type APOL1 nucleic acid.

12. The nucleic acid detection system of claim 11 , wherein the crRNA comprises the nucleic acid sequence of any one of crRNAI 0-crRNA35.

13. The nucleic acid detection system of claim 11 , wherein the crRNA comprises the nucleic acid sequence of any one of crRNA38-crRNA45.

14. The nucleic acid detection system of claim 11 , wherein the crRNA comprises the nucleic acid sequence of any one of crRNA46-crRNA66.

15. The nucleic acid detection system of claim 1 , wherein the ratio of Cas nuclease: crRNA is about 2:1 .

16. The nucleic acid detection system of claim 1 , wherein the reporter comprises a fluorophore, a nucleic acid linker, and a quencher.

17. The nucleic acid detection system of claim 16, wherein the reporter comprises5TEX615 / TArArUGC / 3IAbRQSp, 56-FAM / rUrUrUrUrU / 3IABkFQ, 56-FAM / rArArArArA / 3IABkFQ, 5TEX615 / rArArArArA / 3IAbRQSp, 5 Hexachlorofluorescein / TTATT / 3IABkFQ, or carboxyfluorescein / nucleic acid linker / quencher.

18. The nucleic acid detection system of claim 1 , wherein the reporter comprises a fluorophore, a nucleic acid linker, and a binding moiety.

19. The nucleic acid detection system of claim 18, wherein the binding moiety is biotin or digoxigenin.

20. The nucleic acid detection system of claim 19, wherein the reporter comprises 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) or 56-FAM / TTATTATT / 3DigN.21 . The nucleic acid detection system of claim 1 , further comprising an APOL1 target DNA.

22. The nucleic acid detection system of claim 1 , further comprising an APOL1 target RNA.

23. The nucleic acid detection system of claim 1 , further comprising a cleaved reporter.

24. The nucleic acid detection system of claim 1 , comprising:(a) LwaCas13a;(b) crRNA5; and(c) carboxyfluorescein / nucleic acid linker / quencher.

25. The nucleic acid detection system of claim 1 , comprising:(a) PsmCas13b;(b) crRNA22; and(c) 5TEX615 / rArArArArA / 3IAbRQSp.

26. The nucleic acid detection system of claim 1 , comprising:(a) LbaCas12a;(b) crRNA36; and(c) Hexachlorofluorescein / TTATT / 3IABkFQ.

27. The nucleic acid detection system of claim 1 , comprising:(a) a first Cas nuclease, a second Cas nuclease, and a third Cas nuclease;(b) a crRNA that specifically binds to a G1 variant AP0L1 nucleic acid, a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid, and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid; and(c) a reporter cleavable by the first Cas nuclease, a reporter cleavable by the second Cas nuclease, and a reporter cleavable by the third Cas nuclease.

28. The nucleic acid detection system of claim 27, wherein each Cas nuclease is a different Cas nuclease.

29. The nucleic acid detection system of claim 27, further comprising a cleaved reporter.

30. The nucleic acid detection system of claim 27, comprising:(a) LwaCas13a, PsmCas13b, and LbaCas12a;(b) crRNA5, crRNA22, and crRNA36; and(c) carboxyfluorescein / nucleic acid linker / quencher, 5TEX615 / rArArArArA / 3IAbRQSp, and Hexachlorofluorescein / TTATT / 3IABkFQ.31 . The nucleic acid detection system of claim 30, further comprising a cleaved carboxyfluorescein / nucleic acid linker / quencher reporter, a cleaved 5TEX615 / rArArArArA / 3IAbRQSp reporter, or a cleaved Hexachlorofluorescein / TTATT / 3IABkFQ reporter.

32. The nucleic acid detection system of claim 1 , comprising:(a) a first Cas nuclease and a second Cas nuclease;(b) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid and a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid; and(c) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease.

33. The nucleic acid detection system of claim 32, wherein each Cas nuclease is a different Cas nuclease.

34. The nucleic acid detection system of claim 32, further comprising a cleaved reporter.

35. The nucleic acid detection system of claim 32, comprising:(a) LwaCas13a and LbaCas12a;(b) crRNA5 and crRNA41 ; and(c) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN.

36. The nucleic acid detection system of claim 35, further comprising a cleaved 56- FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

37. The nucleic acid detection system of claim 1 , comprising:(a) a first Cas nuclease and a second Cas nuclease;(b) a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid; and(c) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease.

38. The nucleic acid detection system of claim 37, wherein each Cas nuclease is a different Cas nuclease.

39. The nucleic acid detection system of claim 37, further comprising a cleaved reporter.

40. The nucleic acid detection system of claim 37, comprising:(a) LwaCas13a and LbaCas12a;(b) crRNA62 and crRNA36; and(c) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN.41 . The nucleic acid detection system of claim 40, further comprising a cleaved 56- FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

42. A lateral flow strip comprising:(a) the nucleic acid detection system of any one of claims 1 -41 ;(b) an application area;(c) one or more capture areas comprising an immobilized reagent; and(d) a control area.

43. The lateral flow strip of claim 42, wherein the application area comprises nanoparticles comprising a plasmon-resonance causing metal, wherein the surface of the nanoparticle comprises an antibody that binds the reporter.

44. The lateral flow strip of claim 43, wherein the plasmon-resonance causing metal comprises gold.

45. The lateral flow strip of claim 43, wherein the surface of the nanoparticle comprises an anti-Fam antibody.

46. The lateral flow strip of claim 43, wherein the control area comprises a secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle.

47. The lateral flow strip of claim 46, wherein the control area comprises a secondary anti-species specific antibody that binds the anti-Fam antibody.

48. The lateral flow strip of claim 42, comprising a first capture area that comprises streptavidin and a second capture area that comprises anti-digoxigenin.

49. The lateral flow strip of claim 42, comprising:(a) a nucleic acid detection system comprising:(i) a first Cas nuclease and a second Cas nuclease;(ii) a crRNA that specifically binds to a G1 variant APOL1 nucleic acid and a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid; and(iii) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease;(b) an application area comprising nanoparticles comprising a plasmon-resonance causing metal, wherein the surface of the nanoparticle comprises an antibody that binds the reporter;(c) a capture area comprising a first immobilized reagent;(d) a capture area comprising a second immobilized reagent; and(e) a control area comprising a secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle.

50. The lateral flow strip of claim 49, wherein each Cas nuclease is a different Cas nuclease.51 . The lateral flow strip of claim 49, wherein the nucleic acid detection system further comprises a cleaved reporter.

52. The lateral flow strip of claim 42, comprising:(a) a nucleic acid detection system comprising:(i) LwaCas13a and LbaCas12a;(ii) crRNA5 and crRNA41 ; and(iii) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN;(b) an application area comprising anti-Fam gold nanoparticles (AuNPs);(c) a capture area comprising streptavidin;(d) a capture area comprising anti-digoxigenin; and(e) a control area comprising a secondary anti-species specific antibody that binds AuNPs.

53. The lateral flow strip of claim 52, wherein the nucleic acid detection system further comprises a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

54. The lateral flow strip of claim 42, comprising:(a) a nucleic acid detection system comprising:(i) a first Cas nuclease and a second Cas nuclease;(ii) a crRNA that specifically binds to a GO wild-type APOL1 nucleic acid and a crRNA that specifically binds to a G2 variant APOL1 nucleic acid; and(iii) a reporter cleavable by the first Cas nuclease and a reporter cleavable by the second Cas nuclease;(b) an application area comprising nanoparticles comprising a plasmon-resonance causing metal, wherein the surface of the nanoparticle comprises an antibody that binds the reporter;(c) a capture area comprising a first immobilized reagent;(d) a capture area comprising a second immobilized reagent; and(e) a control area comprising a secondary anti-species specific antibody that binds the antibody on the surface of the nanoparticle.

55. The lateral flow strip of claim 54, wherein each Cas nuclease is a different Cas nuclease.

56. The lateral flow strip of claim 54, wherein the nucleic acid detection system further comprises a cleaved reporter.

57. The lateral flow strip of claim 42, comprising:(a) a nucleic acid detection system comprising:(i) LwaCas13a and LbaCas12a;(ii) crRNA62 and crRNA36; and(iii) 56-FAM / UUUUUUUUUUUUUU / 3Bio (SEQ ID NO: 91 ) and 56-FAM / TTATTATT / 3DigN;(b) an application area comprising anti-Fam gold nanoparticles (AuNPs);(c) a capture area comprising streptavidin;(d) a capture area comprising anti-digoxigenin; and(e) a control area comprising a secondary anti-species specific antibody that binds AuNPs.

58. The lateral flow strip of claim 57, wherein the nucleic acid detection system further comprises a cleaved 56-FAM / UUUUUUUUUUUUUU / 3Bio reporter or a cleaved 56-FAM / TTATTATT / 3DigN reporter.

59. A kit comprising one or more of the nucleic acid detection system of any one of claims 1 -41 .

60. A kit comprising one or more of the lateral flow strips claim 42.61 . The kit of claim 59, comprising the lateral flow strip of claim 48 and the lateral flow strip of claim 54.

62. The kit of claim 59, further comprising a genomic DNA isolation component.

63. The kit of claim 59, further comprising an amplification component.

64. The kit of claim 63, wherein the amplification component comprises a DNA polymerase, a forward primer comprising the sequence of F9, and a reverse primer comprising the sequence of R7.

65. A method for determining a subject’s APOL1 genotype, comprising contacting a sample from the subject with the nucleic acid detection system of claim 1 , the lateral flow strip of claim 42, or the kit of claim 59.

66. The method of claim 65, wherein the sample is a blood sample or a saliva sample.

67. The method of claim 66, wherein the genomic DNA of the sample is purified.

68. The method of claim 66, wherein the genomic DNA of the sample is amplified.

69. A method for determining a subject’s APOL1 genotype, comprising:(a) providing an amplified blood sample from a subject;(b) incubating the amplified blood sample with the nucleic acid detection system of claim 1 ; and(c) detecting the reporter in said sample, thereby determining the subject’s APOL1 genotype.

70. The method of claim 69, wherein the detecting comprises measuring the fluorescence of the reporter.71 . A method for determining a subject’s APOL1 genotype, comprising:(a) providing an amplified blood sample from a subject;(b) incubating the amplified blood sample with the nucleic acid detection system of claim 1 ;(c) applying the reaction of step (b) to a lateral flow strip;(d) detecting the reporter in the lateral flow strip, thereby determining the subject’s APOL1 genotype.

72. The method of claim 71 , wherein the detecting comprises determining the presence or absence of a band in the capture area of the lateral flow strip.

Citation Information

Patent Citations

  • Prader-Willi Syndrome detection kit and use method thereof

    CN111041084A

  • Assays and methods for detection of nucleic acids

    US20220325363A1

  • Compositions and methods of a nuclease chain reaction for nucleic acid detection

    WO2021236651A1

  • Enhanced guide nucleic acids and methods of use

    WO2022241032A1